

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 03/044057 A2

(51) International Patent Classification⁷: **C07K 14/705**

(21) International Application Number: PCT/IB02/04924

(22) International Filing Date: 29 October 2002 (29.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/332,119 21 November 2001 (21.11.2001) US

(71) Applicant (*for all designated States except US*): **GENSET S.A.** [FR/FR]; Intellectual Property Department, 24, rue Royale, F-75008 Paris (FR).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **LUCAS, John** [US/US]; 339 The Valley Road, Concord, MA 01742 (US).

(74) Common Representative: **GENSET S.A.**; c/o De Luca, Giampiero, Serono International S.A., Intellectual Property, 12, Chemin des Aulx, 1228 Plan-les-Ouates (CH).

(81) Designated States (*national*): AF, AG, AI., AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PI, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF OBG3 FOR PROMOTING CENTRAL NERVOUS SYSTEM REMYELINATION

(57) Abstract: The present invention relates to the field of central nervous system (CNS) research. Demyelination of neuronal axons within the CNS underlies the pathogenesis of degenerative diseases of the neuromuscular system, such as multiple sclerosis and hereditary leukodystrophies. Therefore, treatments aimed towards accelerating the repair of myelin sheaths offer a potential therapeutic to ameliorate the symptoms of multiple sclerosis and leukodystrophies. A compound, globular OBG3, has been identified that has immunosuppressive properties. This compound should be effective for accelerating the rate of remyelination and treating multiple sclerosis and leukodystrophies.

WO 03/044057 A2



**USE OF OBG3
FOR PROMOTING CENTRAL NERVOUS SYSTEM REMYELINATION**

5

RELATED APPLICATION INFORMATION

This application claims priority on United States provisional patent application Serial No. 60/332,119, filed November 21, 2000, entitled "Use of OBG3 for promoting central nervous system remyelination".

10

FIELD OF THE INVENTION

The present invention relates to the field of central nervous system research, in particular the discovery of compounds effective for accelerating the repair of myelin sheaths of demyelinated neurons and useful for treating multiple sclerosis and hereditary leukodystrophies.

BACKGROUND OF THE INVENTION

15

The following discussion is intended to facilitate the understanding of the invention, but is not intended nor admitted to be prior art to the invention.

20

Demyelinating diseases are those in which myelin is the primary target. They fall into two main groups: acquired diseases and hereditary metabolic disorders. The most common acquired disease is multiple sclerosis (MS), a chronic, frequently progressive, inflammatory central nervous system (CNS) disease characterized pathologically by primary demyelination, usually without initial axonal injury. The etiology and pathogenesis of MS are unknown. Several immunological features of MS, and its moderate association with certain major histocompatibility complex alleles, have prompted the speculation that MS is an immune-mediated disease.

25

The hereditary metabolic disorders include eight identified leukodystrophies: metachromatic leukodystrophy, Refsum's disease, adrenoleukodystrophy, Krabbe's disease, phenylketonuria, Canavan disease, Pelizaeus-Merzbacher disease, and Alexander's disease. The first six are storage disorders. The lack or the malfunctioning of an enzyme causes a toxic buildup of chemical substances. The etiology of Pelizaeus-Merzbacher disease and Alexander's disease, on the other hand, remains unknown.

30

The limited efficacy of current therapies for MS and other demyelinating diseases has stimulated interest in novel therapies to ameliorate these diseases. However, due to the apparently complex etiopathogenesis of these diseases, potentially involving both environmental and autoimmune factors, the need still exists for an effective treatment of these demyelinating disorders.

SUMMARY OF THE INVENTION

35

The instant invention is based on the discovery that portions of the full-length OBG3 polypeptide, termed OBG3 polypeptide fragments or gOBG3 polypeptide fragments, have unexpected effects *in vitro* and *in vivo*, including utility for remyelination and immunosuppression in humans and other mammals. These unexpected effects of OBG3 or gOBG3 polypeptide fragment administration in mammals also include reduction of elevated free fatty acid levels caused by administration of epinephrine, *i.v.* injection of "intralipid", or administration of a high fat test meal,

as well as increased fatty acid oxidation in muscle cells, and weight reduction in mammals consuming a high fat/high sucrose diet. These effects are unexpected and surprising given that administration of full-length OBG3 polypeptide typically has no effect or a significantly reduced effect *in vivo* or *in vitro* depending on the specific biological activity and the amount administered.

5 To the extent that any effect is observed following administration of full-length OBG3 polypeptide, the levels of full-length OBG3 polypeptide required for an effect render it unfeasible in most instances as a potential treatment for humans at this time. In contrast, the OBG3 and gOBG3 polypeptide fragments of the invention are radically more effective and thus can be provided at levels that are feasible for treatments in humans.

10 Thus, the invention is drawn to OBG3 and gOBG3 polypeptide fragments, polynucleotides encoding said OBG3 and gOBG3 polypeptide fragments, vectors comprising said OBG3 and gOBG3 polynucleotides, and cells recombinant for said OBG3 and gOBG3 polynucleotides, as well as to pharmaceutical and physiologically acceptable compositions comprising said OBG3 and gOBG3 polypeptide fragments and methods of administering said OBG3 and gOBG3
15 pharmaceutical and physiologically acceptable compositions in order to accelerate the rate of remyelination in the central nervous system.

In a first aspect, the invention features a purified, isolated, or recombinant OBG3 or gOBG3 polypeptide fragment that that has significantly greater activity than a full-length OBG3 polypeptide, wherein said activity is accelerating the rate of remyelination of demyelinated neurons in a mammal
20 or human. In preferred embodiments, said polypeptide fragment comprises, consists essentially of, or consists of, at least 6 and not more than 238 consecutive amino acids of SEQ ID NO:6 or at least 6 and not more than 241 consecutive amino acids of SEQ ID NO:2 or SEQ ID NO:4. In other preferred embodiments, OBG3 or gOBG3 polypeptide fragments having unexpected activity are selected from amino acids 84-244, 85-244, 86-244, 87-244, 88-244, 89-244, 90-244, 91-244, 92-
25 244, 93-244, 94-244, 95-244, 96-244, 97-244, 98-244, 99-244, 100-244, 101-244, 102-244, or 103-244 of SEQ ID NO:6. In other preferred embodiments, OBG3 or gOBG3 polypeptide fragments having unexpected activity are selected from amino acids 88-247, 89-247, 90-247, 91-247, 92-247, 93-247, 94-247, 95-247, 96-247, 97-247, 98-247, 99-247, 100-247, 101-247, 102-247, 103-247, 104-247, 105-247, or 106-247 of SEQ ID NO:2 or SEQ ID NO:4. In other preferred embodiments,
30 OBG3 or gOBG3 polypeptide fragments are selected from amino acids about 84 to 244, 85 to 244, 101 to 244, 102 to 244, or 103 to 244 of SEQ ID NO:6 and amino acids 88 to 247, 104 to 247, 105 to 247, or 106 to 247 of SEQ ID NO:2 or SEQ ID NO:4. In further preferred embodiments, gOBG3 polypeptide fragments are said selected gOBG3 polypeptide fragments made resistant to dipeptidyl
35 polypeptide fragment comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the corresponding consecutive amino acids of SEQ ID NO:6, SEQ ID NO:2 or SEQ ID NO:4.

In other highly preferred embodiments, said polypeptide fragment comprises, consists essentially of, or consists of, a purified, isolated, or recombinant gOBG3 fragment. Preferably, said gOBG3 polypeptide fragment comprises, consists essentially of, or consists of, at least 6 consecutive amino acids of amino acids 84 to 244 of SEQ ID NO:6 or at least 6 consecutive amino acids of amino acids 88 to 247 of SEQ ID NO:2 or SEQ ID NO:4. In other preferred embodiments, gOBG3 polypeptide fragments having unexpected activity are selected from amino acids 84-244, 85-244, 86-244, 87-244, 88-244, 89-244, 90-244, 91-244, 92-244, 93-244, 94-244, 95-244, 96-244, 97-244, 98-244, 99-244, 100-244, 101-244, 102-244, or 103-244 of SEQ ID NO:6. In other preferred embodiments, gOBG3 polypeptide fragments having unexpected activity are selected from amino acids 88-247, 89-247, 90-247, 91-247, 92-247, 93-247, 94-247, 95-247, 96-247, 97-247, 98-247, 99-247, 100-247, 101-247, 102-247, 103-247, 104-247, 105-247, or 106-247 of SEQ ID NO:2 or SEQ ID NO:4. In other preferred embodiments, gOBG3 polypeptide fragments are selected from amino acids 84 to 244, 85 to 244, 101 to 244, 102 to 244, or 103 to 244 of SEQ ID NO:6 and amino acids 88 to 247, 104 to 247, 105 to 247, or 106 to 247 of SEQ ID NO:2 or SEQ ID NO:4. In further preferred embodiments, gOBG3 polypeptide fragments are said selected gOBG3 polypeptide fragments made resistant to dipeptidyl peptidase cleavage by N-terminal modification. Alternatively, said gOBG3 fragment comprises, consists essentially of, or consists of, an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the corresponding amino acids 84 to 244 of SEQ ID NO:6 or at least 75% identical to amino acids 88 to 247 of SEQ ID NO:2 or SEQ ID NO:4. In a further preferred embodiment, the OBG3 polypeptide fragment is identical to an APM1 proteolytic cleavage product from human plasma. Preferably, the proteolytic cleavage product comprises the C1q globular head or a portion thereof. More preferably, the proteolytic cleavage product is identical to a proteolytic cleavage product isolated from human plasma by immunoprecipitation using antibodies specific for the C1q globular head. More preferably the proteolytic cleavage product cannot be immunoprecipitated from human plasma using an antibody directed against the human non-homologous region (HDQETTTQGPGVLLPLPKGA) of APM1. Still more preferably, the APM1 proteolytic cleavage product has an apparent molecular weight of 27 kDa using SDS-PAGE.

In another aspect, the present invention is also directed towards polypeptide fragments of OBG3 having biological activity. Preferred polypeptide fragment is amino acids 166-193 or further fragments thereof. Particularly preferred polypeptide fragment is amino acids 166-176. Other particularly preferred fragment is 167-176.

In a further preferred embodiment, the OBG3 or gOBG3 polypeptide fragment is able to increase the rate of cellular division of oligodendrocyte progenitor cells in a mammal or human.

Further preferred OBG3 or gOBG3 polypeptide fragments are those that increase the rate of migration of oligodendrocyte progenitor cells from the germinal centers to demyelinated axons in the CNS of a mammal or human.

Further preferred OBG3 or gOBG3 polypeptide fragments are those that induce oligodendrocyte progenitor cells to differentiate into mature dendrocytic cells at sites of demyelination in axons of in the CNS of a mammal or a human.

Further preferred OBG3 or gOBG3 polypeptide fragments are those that significantly reduce or eliminate the symptoms of multiple sclerosis in a mammal or human.

Further preferred OBG3 or gOBG3 polypeptide fragments are those that significantly reduce or eliminate the symptoms of hereditary leukodystrophies, which include metachromatic leukodystrophy, Refsum's disease, adrenoleukodystrophy, Krabbe's disease, phenylketonuria, Canavan disease, Pelizaeus-Merzbacher disease, and Alexander's disease.

Further preferred OBG3 or gOBG3 polypeptide fragments are those that form multimers (e.g., heteromultimers or homomultimers) in vitro and/or in vivo. Preferred multimers are homodimers or homotrimers. Other preferred multimers are homomultimers comprising at least 4, 6, 8, 9, 10, or 12 OBG3 or gOBG3 polypeptide fragment subunits. Other preferred mulimers are hetero multimers comprising a OBG3 or gOBG3 polypeptide fragment of the invention.

Further preferred embodiments include heterologous polypeptides comprising an OBG3 or gOBG3 polypeptide fragment of the invention.

In a further embodiment, the invention features a pharmaceutical or physiologically acceptable composition comprising, consisting essentially of, or consisting of, said OBG3 or gOBG3 polypeptide fragment described in the first aspect and, alternatively, a pharmaceutical or physiologically acceptable diluent.

In a further embodiment, the invention features a method for the production of a pharmaceutical or physiologically acceptable composition consisting essentially of, or consisting of, said OBG3 or gOBG3 polypeptide fragment described in the first aspect and, alternatively, a pharmaceutical or physiologically acceptable diluent.

Full-length OBG3 (ACRP30, AdipoQ, APM1) polypeptides and polynucleotides encoding the same may be specifically substituted for an OBG3 or gOBG3 polypeptide fragment or polynucleotide encoding the same in any embodiment of the present invention.

PREFERRED EMBODIMENTS OF THE INVENTION

I. OBG3 Polypeptide Fragments of the Invention

The invention is drawn, *inter alia*, to isolated, purified or recombinant OBG3 polypeptide fragments. OBG3 polypeptide fragments of the invention are useful for accelerating the regeneration of myelin sheaths in vivo. OBG3 polypeptide fragments are also useful *inter alia* in screening assays for agonists or antagonists of OBG3 fragment activity; in screening assays for antagonists of dipeptidyl peptidase cleavage of OBG3 fragments, preferably cleavage of the N-

terminal EP dipeptide of OBG3 polypeptide fragment 103-244 of SEQ ID NO:6, cleavage of the N-terminal VP dipeptide of OBG3 fragment 85-244 of SEQ ID NO:6, or cleavage of the N-terminal EP dipeptide of OBG3 polypeptide fragment 106-247 of SEQ ID NO:2 or SEQ ID NO:4; for raising OBG3 fragment-specific antibodies; and in diagnostic assays.

5 The full-length OBG3 polypeptide is comprised of at least four distinct regions including:

1. an N-terminal putative signal sequence about from amino acids 1-17 of SEQ ID NO:6, SEQ ID NO:2, or SEQ ID NO:4;
2. a unique region about from amino acids 18-41 of SEQ ID NO:6 or 18-44 of SEQ ID NO:2, or SEQ ID NO:4;
- 10 3. a collagen-like region about from amino acids 42-107 of SEQ ID NO:6 or 45-110 of SEQ ID NO:2 or SEQ ID NO:4; and
4. a globular region about from amino acids 108-244 of SEQ ID NO:6 or 111-247 of SEQ ID NO:2 or SEQ ID NO:4.

15 The term "collagen residues" is used in the manner standard in the art to mean the amino acid triplet glycine, X, Y, where X and Y can be any amino acid.

 The OBG3 polypeptide fragments of the present invention are preferably provided in an isolated form, and may be partially or substantially purified. A recombinantly produced version of an OBG3 polypeptide fragment can be substantially purified by the one-step method described by Smith et al. ((1988) Gene 67(1):31-40) or by the methods described herein or known in the art (see, 20 e.g., Examples 1-3). Fragments of the invention also can be purified from natural or recombinant sources using antibodies directed against the polypeptide fragments of the invention by methods known in the art of protein purification.

 Preparations of OBG3 polypeptide fragments of the invention involving a partial purification of or selection for the OBG3 polypeptide fragments are also specifically contemplated. 25 These crude preparations are envisioned to be the result of the concentration of cells expressing OBG3 polypeptide fragments with perhaps a few additional purification steps, but prior to complete purification of the fragment. The cells expressing OBG3 polypeptide fragments are present in a pellet, they are lysed, or the crude polypeptide is lyophilized, for example.

 OBG3 or gOBG3 polypeptide fragments can be any integer in length from at least 6 30 consecutive amino acids to 1 amino acid less than a full-length OBG3 polypeptide. Thus, for human OBG3 (SEQ ID NO: 6), an OBG3 or gOBG3 polypeptide fragment can be any integer of consecutive amino acids from 6 to 243; for mouse OBG3 (SEQ ID NO:2 or SEQ ID NO:4) an OBG3 or gOBG3 fragment can be any integer of consecutive amino acids from 6 to 246, for example. The term "integer" is used herein in its mathematical sense and thus representative 35 integers include: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,

83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, and 246.

Each OBG3 fragment as described above can be further specified in terms of its N-terminal and C-terminal positions. For example, every combination of a N-terminal and C-terminal position that fragments of from 6 contiguous amino acids to 1 amino acids less than the full-length OBG3 polypeptide could occupy, on any given intact and contiguous full-length OBG3 polypeptide sequence are included in the present invention. Thus, a 6 consecutive amino acid fragment could occupy positions selected from the group consisting of 1-6, 2-7, 3-8, 4-9, 5-10, 6-11, 7-12, 8-13, 9-14, 10-15, 11-16, 12-17, 13-18, 14-19, 15-20, 16-21, 17-22, 18-23, 19-24, 20-25, 21-26, 22-27, 23-28, 24-29, 25-30, 26-31, 27-32, 28-33, 29-34, 30-35, 31-36, 32-37, 33-38, 34-39, 35-40, 36-41, 37-42, 38-43, 39-44, 40-45, 41-46, 42-47, 43-48, 44-49, 45-50, 46-51, 47-52, 48-53, 49-54, 50-55, 51-56, 52-57, 53-58, 54-59, 55-60, 56-61, 57-62, 58-63, 59-64, 60-65, 61-66, 62-67, 63-68, 64-69, 65-70, 66-71, 67-72, 68-73, 69-74, 70-75, 71-76, 72-77, 73-78, 74-79, 75-80, 76-81, 77-82, 78-83, 79-84, 80-85, 81-86, 82-87, 83-88, 84-89, 85-90, 86-91, 87-92, 88-93, 89-94, 90-95, 91-96, 92-97, 93-98, 94-99, 95-100, 96-101, 97-102, 98-103, 99-104, 100-105, 101-106, 102-107, 103-108, 104-109, 105-110, 106-111, 107-112, 108-113, 109-114, 110-115, 111-116, 112-117, 113-118, 114-119, 115-120, 116-121, 117-122, 118-123, 119-124, 120-125, 121-126, 122-127, 123-128, 124-129, 125-130, 126-131, 127-132, 128-133, 129-134, 130-135, 131-136, 132-137, 133-138, 134-139, 135-140, 136-141, 137-142, 138-143, 139-144, 140-145, 141-146, 142-147, 143-148, 144-149, 145-150, 146-151, 147-152, 148-153, 149-154, 150-155, 151-156, 152-157, 153-158, 154-159, 155-160, 156-161, 157-162, 158-163, 159-164, 160-165, 161-166, 162-167, 163-168, 164-169, 165-170, 166-171, 167-172, 168-173, 169-174, 170-175, 171-176, 172-177, 173-178, 174-179, 175-180, 176-181, 177-182, 178-183, 179-184, 180-185, 181-186, 182-187, 183-188, 184-189, 185-190, 186-191, 187-192, 188-193, 189-194, 190-195, 191-196, 192-197, 193-198, 194-199, 195-200, 196-201, 197-202, 198-203, 199-204, 200-205, 201-206, 202-207, 203-208, 204-209, 205-210, 206-211, 207-212, 208-213, 209-214, 210-215, 211-216, 212-217, 213-218, 214-219, 215-220, 216-221, 217-222, 218-223, 219-224, 220-225, 221-226, 222-227, 223-228, 224-229, 225-230, 226-231, 227-232, 228-233, 229-234, 230-235, 231-236, 232-237, 233-238, 234-239, 235-240, 236-241, 237-242, 238-243, and 239-244 of SEQ ID NO:6. A 238 consecutive amino acid fragment could occupy positions selected from the group consisting of 1-238, 2-239, 3-240, 4-241, 5-242, 6-243 and 7-244 of SEQ ID NO:6. Similarly, the positions occupied by all the other fragments of sizes between 6 amino acids and 243 amino acids on

SEQ ID NO:6 are included in the present invention and can also be immediately envisaged based on these two examples and therefore, are not individually listed solely for the purpose of not unnecessarily lengthening the specification. Furthermore, the positions occupied by fragments of 6 to 241 consecutive amino acids on SEQ ID NO:2 or SEQ ID NO:4 are included in the present invention and can also be immediately envisaged based on these two examples and therefore are not individually listed solely for the purpose of not unnecessarily lengthening the specification. In addition, the positions occupied by fragments of 6 consecutive amino acids to 1 amino acid less than any other full-length OBG3 polypeptide can also be envisaged based on these two examples and therefore are not individually listed solely for the purpose of not unnecessarily lengthening the specification. In preferred embodiments, OBG3 or gOBG3 polypeptide fragments having unexpected activity are selected from amino acids 84-244, 85-244, 86-244, 87-244, 88-244, 89-244, 90-244, 91-244, 92-244, 93-244, 94-244, 95-244, 96-244, 97-244, 98-244, 99-244, 100-244, 101-244, 102-244, or 103-244 of SEQ ID NO:6. In preferred embodiments, OBG3 or gOBG3 polypeptide fragments having unexpected activity are selected from amino acids 88-247, 89-247, 90-247, 91-247, 92-247, 93-247, 94-247, 95-247, 96-247, 97-247, 98-247, 99-247, 100-247, 101-247, 102-247, 103-247, 104-247, 105-247, or 106-247 of SEQ ID NO:2 or SEQ ID NO:4.

The OBG3 or gOBG3 polypeptide fragments of the present invention may alternatively be described by the formula "n to c" (inclusive); where "n" equals the N-terminal most amino acid position (as defined by the sequence listing) and "c" equals the C-terminal most amino acid position (as defined by the sequence listing) of the polypeptide; and further where "n" equals an integer between 1 and the number of amino acids of the full length polypeptide sequence of the present invention minus 6 (238 for SEQ ID NO: 6 and 241 for SEQ ID NOs: 2 or 4); and where "c" equals an integer between 7 and the number of amino acids of the full-length polypeptide sequence (244 for SEQ ID NO: 6 and 247 for SEQ ID NOs: 2 or 4); and where "n" is an integer smaller than "c" by at least 6. Therefore, for SEQ ID NO: 6, "n" is any integer selected from the list consisting of: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 234, 235, 236, 237 and 238; and "c" is any integer selected from the group consisting of: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,

34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244. Every combination of “n” and “c” positions are included as specific embodiments of the invention. Moreover, the formula “n” to “c” may be modified as “n1 – n2” to “c1 – c2”, wherein “n1 – n2” and “c1 – c2” represent positional ranges selected from any two integers above which represent amino acid positions of the sequence listing. Alternative formulas include “n1 – n2” to “c” and “n” to “c1 – c2”. In preferred embodiment, OBG3 or gOBG3 polypeptide fragments of the invention may be described by the formula where n1=84, n2=103, and c=244 of SEQ ID NO:6 or by the formula n1=88, n2=106, and c=247 of SEQ ID NO: 2 or SEQ ID NO:4.

These specific embodiments, and other polypeptide and polynucleotide fragment embodiments described herein may be modified as being “at least”, “equal to”, “equal to or less than”, “less than”, “at least ___ but not greater than ___” or “from ___ to ___”. a specified size or specified N-terminal and/or C-terminal positions. It is noted that all ranges used to describe any embodiment of the present invention are inclusive unless specifically set forth otherwise.

The present invention also provides for the exclusion of any individual fragment specified by N-terminal and C-terminal positions or of any fragment specified by size in amino acid residues as described above. In addition, any number of fragments specified by N-terminal and C-terminal positions or by size in amino acid residues as described above may be excluded as individual species. Further, any number of fragments specified by N-terminal and C-terminal positions or by size in amino acid residues as described above may make up a polypeptide fragment in any combination and may optionally include non-OBG3 polypeptide sequence as well.

In particularly preferred embodiments, the OBG3 polypeptide fragment is a “globular OBG3” (gOBG3) fragment. The term “gOBG3 fragment” or “gOBG3” or “gOBG3 polypeptide” as used herein refers to fragments of a full-length OBG3 polypeptide that comprise at least 6 and any other integer number of amino acids up to 137 of the globular region of a full-length OBG3 polypeptide (defined above). In preferred embodiments, gOBG3 polypeptide fragments also comprise at least 1 and any other integer number of amino acids up 66 of the collagen region of a full-length OBG3 polypeptide, preferably 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, 23, or 24 consecutive amino acid residues from the collagen region of the intact OBG3 polypeptide

that are adjacent to the globular region. By "adjacent" to the globular region is meant the first collagen amino acid immediately N-terminal to the globular region and adding each collagen amino acid consecutively in the N-terminal direction. Thus, for example, if there is only one collagen amino acid in the gOBG3 polypeptide fragment, it is the collagen amino acid 107 of SEQ ID NO: 6 or amino acid 110 of SEQ ID NO:2 or SEQ ID NO:4 located adjacent and 5' to the first amino acid of the globular region. If there are 24 collagen amino acids adjacent to the globular region in the gOBG3 fragment they would be the collagen amino acids 84-107 of SEQ ID NO: 6 or amino acids 87-110 of SEQ ID NO:2 or SEQ ID NO:4.

In preferred embodiments, OBG3 or gOBG3 polypeptide fragments having unexpected activity are selected from amino acids 84-244, 85-244, 86-244, 87-244, 88-244, 89-244, 90-244, 91-244, 92-244, 93-244, 94-244, 95-244, 96-244, 97-244, 98-244, 99-244, 100-244, 101-244, 102-244, or 103-244 of SEQ ID NO:6. In other preferred embodiments, OBG3 or gOBG3 polypeptide fragments having unexpected activity are selected from amino acids 88-247, 89-247, 90-247, 91-247, 92-247, 93-247, 94-247, 95-247, 96-247, 97-247, 98-247, 99-247, 100-247, 101-247, 102-247, 103-247, 104-247, 105-247, or 106-247 of SEQ ID NO:2 or SEQ ID NO:4. In further preferred embodiments, gOBG3 polypeptide fragments are selected from amino acids 84 to 244, 85 to 244, 101 to 244, 102 to 244, or 103 to 244 of SEQ ID NO:6 and amino acids 88 to 247, 104 to 247, 105 to 247, or 106 to 247 of SEQ ID NO:2 or SEQ ID NO:4. In yet other preferred embodiments, the invention features a gOBG3 polypeptide fragment comprising at least 115, but not more than 175 contiguous amino acids of any one of the gOBG3 fragment sequences set forth in Figure 1, wherein no more than 24 of said at least 115 and no more than 175 contiguous amino acids are present in the collagen-like region of OBG3. Preferably, the gOBG3 polypeptide fragment comprises at least 125, but not more than 165, or at least 140, but not more than 165 amino acids, and no more than 24 amino acids are in the collagen-like region; more preferably at least 125 but not more than 165, or at least 140 but not more than 165 amino acids, and no more than 12 amino acids are in the collagen-like region; or at least 140 and not more than 150 amino acids, and no more than 8 amino acids are present in the collagen-like region. Preferably the gOBG3 fragment is mammalian, preferably human or mouse, but most preferably human.

OBG3 and gOBG3 polypeptide fragments of the invention include variants, fragments, analogs and derivatives of the OBG3 and gOBG3 polypeptide fragments described above, including modified OBG3 and gOBG3 polypeptide fragments. Particularly preferred are proteolytically cleaved fragments of OBG3 of SEQ ID NO:6, SEQ ID NO:2, or SEQ ID NO:4. More preferred is OBG3 fragment of about amino acids 85-244 of SEQ ID NO:6 made by collagenase cleavage of SEQ ID NO:6 at about position 84. More preferred is OBG3 fragment of about amino acids 88-247 of SEQ ID NO:2 or of SEQ ID NO:4 made by collagenase cleavage of SEQ ID NO:2 or SEQ ID NO:4 at about position 87. More preferred is OBG3 fragment of about amino acids 85-244 of SEQ ID NO:6 made by matrix metalloproteinase-1 (MMP-1) cleavage of SEQ ID NO:6 at about position

84. More preferred is OBG3 fragment of about amino acids 88-247 of SEQ ID NO:2 or of SEQ ID NO:4 made by matrix metalloproteinase-1 (MMP-1) cleavage of SEQ ID NO:2 or SEQ ID NO:4 at about position 87. More preferred is OBG3 fragment of about amino acids 101-244 of SEQ ID NO:6 made by plasmin cleavage of SEQ ID NO:6 at about position 100. More preferred is OBG3 fragment of about amino acids 104-247 of SEQ ID NO:2 or of SEQ ID NO:4 made by plasmin cleavage of SEQ ID NO:2 or SEQ ID NO:4 at about position 103. More preferred is OBG3 fragment of about amino acids 103-244 of SEQ ID NO:6 made by precerebellin processing protease cleavage of SEQ ID NO:6 at about position 102. More preferred is OBG3 fragment of about amino acids 106-247 of SEQ ID NO:2 or of SEQ ID NO:4 made by precerebellin processing protease cleavage of SEQ ID NO:2 or SEQ ID NO:4 at about position 105. More preferred is APM1 proteolytic fragment of SEQ ID NO:6, wherein said APM1 fragment isolated from human plasma migrates with an apparent molecular weight of about 27 kDa on SDS-PAGE under reducing conditions. Most preferred are polypeptide fragments possessing biological activity, comprising amino acids 166-193, amino acids 166-176, and amino acids 167-176

15 Variants

It will be recognized by one of ordinary skill in the art that some amino acids of the OBG3 and gOBG3 fragment sequences of the present invention can be varied without significant effect on the structure or function of the protein; there will be critical amino acids in the fragment sequence that determine activity. Thus, the invention further includes variants of OBG3 and gOBG3 polypeptide fragments that have remyelinating activity as described above. Such variants include OBG3 fragment sequences with one or more amino acid deletions, insertions, inversions, repeats, and substitutions either from natural mutations or human manipulation selected according to general rules known in the art so as to have little effect on activity. Guidance concerning how to make phenotypically silent amino acid substitutions is provided below.

25 There are two main approaches for studying the tolerance of an amino acid sequence to change (*see*, Bowie, et al. (1990) Science, 247, 1306-10). The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selections or screens to identify sequences that maintain functionality.

30 These studies have revealed that proteins are surprisingly tolerant of amino acid substitutions and indicate which amino acid changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described by Bowie et al. (*supra*) and the references cited therein.

35 Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Phe; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln;

exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe, Tyr. In addition, the following groups of amino acids generally represent equivalent changes: (1) Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr; (2) Cys, Ser, Tyr, Thr; (3) Val, Ile, Leu, Met, Ala, Phe; (4) Lys, Arg, His; (5) Phe, Tyr, Trp, His.

5 Similarly, amino acids in the OBG3 and gOBG3 polypeptide fragment sequences of the invention that are essential for function can also be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (*see, e.g.*, Cunningham, et al. (1989) Science 244(4908):1081-5). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for obesity-related activity
10 using assays as described above. Of special interest are substitutions of charged amino acids with other charged or neutral amino acids that may produce proteins with highly desirable improved characteristics, such as less aggregation. Aggregation may not only reduce activity but also be problematic when preparing pharmaceutical or physiologically acceptable formulations, because aggregates can be immunogenic (*see, e.g.*, Pinckard, et al., (1967) Clin. Exp. Immunol 2:331-340;
15 Robbins, et al., (1987) Diabetes Jul;36(7):838-41; and Cleland, et al., (1993) Crit Rev Ther Drug Carrier Syst. 10(4):307-77).

Thus, the fragment, derivative, analog, or homolog of the OBG3 or gOBG3 fragment of the present invention may be, for example: (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino
20 acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code (i.e. may be a non-naturally occurring amino acid); or (ii) one in which one or more of the amino acid residues includes a substituent group; or (iii) one in which the OBG3 or gOBG3 fragment is fused with another compound, such as a compound to increase the half-life of the fragment (for example, polyethylene glycol); or (iv) one in which the additional amino acids are fused to the above
25 form of the fragment, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the above form of the fragment or a pro-protein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

A further embodiment of the invention relates to a polypeptide which comprises the amino
30 acid sequence of an OBG3 or gOBG3 polypeptide fragment having an amino acid sequence which contains at least one conservative amino acid substitution, but not more than 50 conservative amino acid substitutions, not more than 40 conservative amino acid substitutions, not more than 30 conservative amino acid substitutions, and not more than 20 conservative amino acid substitutions. Also provided are polypeptides which comprise the amino acid sequence of a OBG3 or gOBG3
35 fragment, having at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 conservative amino acid substitutions.

Another specific embodiment of a modified OBG3 or gOBG3 fragment of the invention is a polypeptide that is resistant to proteolysis, for example a OBG3 or gOBG3 fragment in which a -CONH- peptide bond is modified and replaced by one or more of the following: a (CH₂NH) reduced bond; a (NHCO) retro inverso bond; a (CH₂-O) methylene-oxy bond; a (CH₂-S) thiomethylene bond; a (CH₂CH₂) carba bond; a (CO-CH₂) cetomethylene bond; a (CHOH-CH₂) hydroxyethylene bond); a (N-N) bound; a E-alcene bond; or a -CH=CH- bond. Thus, the invention also encompasses an OBG3 or gOBG3 fragment or a variant thereof in which at least one peptide bond has been modified as described above.

A further embodiment of the invention relates to an OBG3 or gOBG3 polypeptide fragment made resistant to dipeptidyl peptidase cleavage through N-terminal modification of said polypeptide fragment. In preferred embodiment, said OBG3 or gOBG3 polypeptide fragment is selected from amino acids 85-244 or 103-244 of SEQ ID NO:6 or amino acids 106-247 of SEQ ID NO:2 or SEQ ID NO:4. In preferred embodiment, said dipeptidyl peptidase cleavage leads to removal of the N-terminal dipeptide EP by dipeptidyl peptidase from said preferred gOBG3 polypeptide fragment 103-244 of SEQ ID NO:6 or 106-247 of SEQ ID NO:2 or SEQ ID NO:4. In preferred embodiment, said dipeptidyl peptidase cleavage leads to removal of the N-terminal dipeptide VP by dipeptidyl peptidase from said preferred gOBG3 polypeptide fragment 85-244 of SEQ ID NO:6. In preferred embodiment, said dipeptidyl peptidase is human plasma comprised of dipeptidyl peptidase. In preferred embodiment, said dipeptidyl peptidase is selected from but not restricted to human CD26 or human Attractin. In further preferred embodiment, said dipeptidyl peptidase is selected from soluble human CD26 or soluble human Attractin. In preferred embodiment, said N-terminal modification is selected from but not restricted to glycation [Harte (2001) Regulatory Peptides 96:95-104 which disclosure is hereby incorporated by reference in its entirety], N-methylation, alpha-methylation, desamidation [Gallwitz (2000) Regulatory Peptides 86:103-111 which disclosure is hereby incorporated by reference in its entirety], or alternation of the chirality of one or more N-terminal amino acids [Siegel (1999) European Journal of Clinical Investigation 29:610-614 which disclosure is hereby incorporated by reference in its entirety]. Thus, the invention also encompasses an OBG3 or gOBG3 polypeptide fragment or a variant thereof that has been made resistant to dipeptidyl peptidase cleavage through N-terminal modification of said polypeptide fragment.

In addition, amino acids have chirality within the body of either L or D. In some embodiments it is preferable to alter the chirality of the amino acids in the OBG3 or gOBG3 polypeptide fragments of the invention in order to extend half-life within the body. In other embodiments, it is preferable to alter the chirality of one or more amino acid in order to render the OBG3 or gOBG3 polypeptide fragment resistant to dipeptidyl peptidase cleavage [Siegel (1999) European Journal of Clinical Investigation 29:610-614 which disclosure is hereby incorporated by reference in its entirety]. In further embodiments, it is preferable to alter the chirality of the penultimate N-terminal amino acid in order to render the OBG3 or gOBG3 polypeptide fragment

resistant to dipeptidyl peptidase cleavage. Thus, in some embodiments, one or more of the amino acids are preferably in the L configuration. In other embodiments, one or more of the amino acids are preferably in the D configuration.

Percent Identity

5 The polypeptides of the present invention also include polypeptides having an amino acid sequence at least 50% identical, at least 60% identical, or 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an OBG3 or gOBG3 fragment as described above. By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to an OBG3 or gOBG3 fragment amino acid sequence is meant that the amino acid sequence is identical to the
10 OBG3 or gOBG3 polypeptide fragment sequence except that it may include up to five amino acid alterations per each 100 amino acids of the OBG3 or gOBG3 polypeptide fragment amino acid sequence. The reference sequence is the OBG3 or gOBG3 polypeptide fragment with a sequence corresponding to the sequence of the sequence listing. Thus, to obtain a polypeptide having an amino acid sequence at least 95% identical to an OBG3 or gOBG3 fragment amino acid sequence,
15 up to 5% (5 of 100) of the amino acid residues in the sequence may be inserted, deleted, or substituted with another amino acid compared with the OBG3 or gOBG3 polypeptide fragment sequence. These alterations may occur at the amino or carboxy termini or anywhere between those terminal positions, interspersed either individually among residues in the sequence or in one or more contiguous groups within the sequence.

20 As a practical matter, whether any particular polypeptide is a percentage identical to an OBG3 or gOBG3 fragment can be determined conventionally using known computer programs. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, (1988) Proc Natl Acad Sci USA 85(8):2444-8; Altschul et al., (1990) J Mol Biol 215(3):403-410; Thompson et al., (1994) Nucleic
25 Acids Res 22(2):4673-4680; Higgins et al., (1996) Meth Enzymol 266:383-402; Altschul et al., (1997) Nuc Acids Res 25:3389-3402; Altschul et al., (1993) Nature Genetics 3:266-272). In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST"), which is well known in the art (*See, e.g.*, Karlin and Altschul (1990) Proc Natl Acad Sci USA 87(6):2264-8; Altschul et al., 1990, 1993, 1997,
30 all *supra*). In particular, five specific BLAST programs are used to perform the following tasks:

(1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;

(2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;

35 (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;

(4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and

(5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

5 The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (*i.e.*, aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62
10 matrix (see, Gonnet et al., (1992) *Science* 256(5062):1443-5; Henikoff and Henikoff (1993) *Proteins* 17(1):49-61). Less preferably, the PAM or PAM250 matrices may also be used (*See, e.g.*, Schwartz and Dayhoff, eds, (1978) *Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure*, Washington: National Biomedical Research Foundation). The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably
15 selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (*See, e.g.*, Karlin and Altschul, (1990) *Proc Natl Acad Sci USA* 87(6):2264-8). The BLAST programs may be used with the default parameters or with modified parameters provided by the user. Preferably, the parameters are default
20 parameters.

 A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (1990) *Comp. App. Biosci.* 6:237-245. In a sequence alignment the query and subject
25 sequences are both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group=25 Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=247 or the length of the subject amino acid sequence, whichever is shorter.

30 If the subject sequence is shorter than the query sequence due to N-or C-terminal deletions, not because of internal deletions, the results, in percent identity, must be manually corrected because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues
35 of the query sequence that are N- and C- terminal of the subject sequence, that are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence

alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query amino acid residues outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100-residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not match/align with the first residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%.

In another example, a 90-residue subject sequence is compared with a 100-residue query sequence. This time the deletions are internal so there are no residues at the N- or C-termini of the subject sequence, which are not matched/aligned with the query. In this case, the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected. No other manual corrections are made for the purposes of the present invention.

Production

Note, throughout the disclosure, wherever OBG3 polypeptide fragments are discussed, gOBG3 fragments are specifically intended to be included as a preferred subset of OBG3 polypeptide fragments.

OBG3 polypeptide fragments are preferably isolated from human or mammalian tissue samples or expressed from human or mammalian genes in human or mammalian cells. The OBG3 polypeptide fragments of the invention can be made using routine expression methods known in the art. The polynucleotide encoding the desired polypeptide fragments is ligated into an expression vector suitable for any convenient host. Both eukaryotic and prokaryotic host systems are used in forming recombinant polypeptide fragments. The polypeptide fragment is then isolated from lysed cells or from the culture medium and purified to the extent needed for its intended use. Purification is by any technique known in the art, for example, differential extraction, salt fractionation, chromatography, centrifugation, and the like. See, for example, Methods in Enzymology for a variety of methods for purifying proteins. Also, see Examples 1-3 for methods previously used for OBG3 polypeptide fragments.

In an alternative embodiment, the polypeptides of the invention are isolated from milk. The polypeptides can be purified as full-length OBG3 polypeptides, which can then be cleaved, if appropriate, in vitro to generate an OBG3 fragment, or, alternatively, OBG3 fragments themselves can be purified from the milk. Any of a large number of methods can be used to purify the present polypeptides from milk, including those taught in Protein Purification Applications, A Practical Approach (New Edition), Edited by Simon Roe, AEA Technology Products and Systems, Biosciences, Harwell; Clark (1998) J Mammary Gland Biol Neoplasia 3:337-50; Wilkins and Velandier (1992) 49:333-8; U.S. Patent Nos. 6,140,552; 6,025,540; Hennighausen, Protein Expression and Purification, vol. 1, pp. 3-8 (1990); Harris et al. (1997) Bioseparation 7:31-7; Degener et al. (1998) J Chromatog 799:125-37; Wilkins (1993) J Cell Biochem Suppl. 0 (17 part A):39; the entire disclosures of each of which are herein incorporated by reference. In a typical embodiment, milk is centrifuged, e.g. at a relatively low speed, to separate the lipid fraction, and the aqueous supernatant is then centrifuged at a higher speed to separate the casein in the milk from the remaining, "whey" fraction. Often, biomedical proteins are found in this whey fraction, and can be isolated from this fraction using standard chromatographic or other procedures commonly used for protein purification, e.g. as described elsewhere in the present application. In one preferred embodiment, OBG3 polypeptides are purified using antibodies specific to OBG3 polypeptides, e.g. using affinity chromatography. In addition, methods can be used to isolate particular OBG3 fragments, e.g. electrophoretic or other methods for isolating proteins of a particular size. The OBG3 polypeptides isolating using these methods can be naturally occurring, as OBG3 polypeptides have been discovered to be naturally present in the milk of mammals (see, e.g. Example 17), or can be the result of the recombinant production of the protein in the mammary glands of a non-human mammal, as described infra. In one such embodiment, the OBG3 fragment is produced as a fusion protein with a heterologous, antigenic polypeptide sequence, which antigenic sequence can be used to purify the protein, e.g., using standard immuno-affinity methodology.

In addition, shorter protein fragments may be produced by chemical synthesis. Alternatively, the proteins of the invention are extracted from cells or tissues of humans or non-human animals. Methods for purifying proteins are known in the art, and include the use of detergents or chaotropic agents to disrupt particles followed by differential extraction and separation of the polypeptides by ion exchange chromatography, affinity chromatography, sedimentation according to density, and gel electrophoresis.

Any OBG3 fragment cDNA, including that in Fig. 4, can be used to express OBG3 polypeptide fragments. The nucleic acid encoding the OBG3 fragment to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The OBG3 fragment cDNA insert in the expression vector may comprise the coding sequence for: the full-length OBG3 polypeptide (to be later modified); from 6 amino acids to 6 amino acids less than the full-length OBG3 polypeptide; a gOBG3 fragment; or variants and % similar polypeptides.

The expression vector is any of the mammalian, yeast, insect or bacterial expression systems known in the art, some of which are described herein, and examples of which are given in the Examples (Examples 1-3). Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence can be optimized for the particular expression organism into which the expression vector is introduced, as explained by Hatfield, et al., US Patent Number 5,082,767, the disclosures of which are incorporated by reference herein in their entirety.

If the nucleic acid encoding OBG3 polypeptide fragments lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the insert from the OBG3 polypeptide fragment cDNA lacks a poly A signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglII and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion of the gag gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene.

The nucleic acid encoding an OBG3 fragment can be obtained by PCR from a vector containing the OBG3 nucleotide sequence using oligonucleotide primers complementary to the desired OBG3 cDNA and containing restriction endonuclease sequences for Pst I incorporated into the 5' primer and BglIII at the 5' end of the corresponding cDNA 3' primer, taking care to ensure that the sequence encoding the OBG3 fragment is positioned properly with respect to the poly A signal. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXT1, now containing a poly A signal and digested with BglIII. Alternative methods are presented in Examples 1-3.

Transfection of an OBG3 fragment-expressing vector into mouse NIH 3T3 cells is one embodiment of introducing polynucleotides into host cells. Introduction of a polynucleotide encoding a polypeptide into a host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al. ((1986) *Methods in Molecular Biology*, Elsevier Science Publishing Co., Inc., Amsterdam). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector. Methods of expressing OBG3 fragment of the invention in cells are described in Examples 1-3.

A polypeptide of this invention (i.e. an OBG3 or gOBG3 fragment) can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or

ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides of the present invention, and
5 preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells.

Depending upon the host employed in a recombinant production procedure, the polypeptides
10 of the present invention may be glycosylated or may be non-glycosylated. Preferably the polypeptides of the invention are non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after
15 translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In addition to encompassing host cells containing the vector constructs discussed herein, the
20 invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (*e.g.*, coding sequence), and/or to include genetic material (*e.g.*, heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques
25 known in the art may be used to operably associate heterologous control regions (*e.g.*, promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, see, *e.g.*, US Patent Number 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., (1989) Proc Natl Acad Sci USA 86(22):8932-5; Koller et al., (1989)
30 Proc Natl Acad Sci USA 86(22):8927-31; and Zijlstra et al. (1989) Nature 342(6248):435-8; the disclosures of each of which are incorporated by reference in their entireties).

Modifications

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (*See, e.g.*, Creighton, 1983 Proteins. New York, New York: W.H. Freeman and
35 Company; and Hunkapiller et al., (1984) Nature 310(5973):105-11). For example, a relative short fragment of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution

or addition into the fragment sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ -Abu, ϵ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, 5 citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoroamino acids, designer amino acids such as β -methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptide fragments which are differentially modified during 10 or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH_4 ; acetylation, formylation, oxidation, reduction; 15 metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a 20 result of procaryotic host cell expression. The polypeptide fragments may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the polypeptide.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention that may provide additional advantages such as increased solubility, stability and 25 circulating time of the polypeptide, or decreased immunogenicity. See U.S. Patent No: 4,179,337. The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more 30 attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may 35 be used, depending on the desired therapeutic profile (*e.g.*, the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the polypeptide with consideration of effects on functional or antigenic domains of the polypeptide. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al. (1992) Exp Hematol 20(8):1028-35, reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues, glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus may be accomplished by reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

In further preferred embodiment, the invention features a method of reducing body mass comprising providing or administering to individuals in need of reducing body mass said pharmaceutical or physiologically acceptable composition described in the fifth aspect in combination with provision or administration of an antagonist of dipeptidyl peptidase cleavage of OBG3 or gOBG3 polypeptide fragment of the first aspect.

Preferred said antagonist is a peptidyl derivative of a diester of alpha-aminoalkylphosphonic acid (US Patent Number 5,543,396 which disclosure is hereby incorporated by reference in its entirety). More preferred said peptidyl derivative is selected from Ala-Pro^P(OZ)₂, AcOH.Ala-Pip^P(Oph)₂, HCl.Ala-Pro^P(Oph-4Cl)₂, HCl.Ala-Pip^P(Oph-4Cl)₂, or 2HCl.Lys-Pip^P(Oph-4Cl)₂, where Z represents an aryl group, a substituted aryl group or a highly fluorinated alkyl group, Pro^P represents a proline phosphonate derivative, and Pip^P represents piperidyl phosphonate (US Patent Number 5,543,396 which disclosure is hereby incorporated by reference in its entirety).

Other preferred said antagonist is a compound of the general formula Z-Xaa-Y', in which Xaa is an amino acid, Z is a protecting group, and Y' is one of various types of ring structures (US Patent Number 6,090,786 which disclosure is hereby incorporated by reference in its entirety). More preferred is said compound wherein Z may or may not be present and represents a protecting group, such as benzyloxycarbonyl; Xaa represents alanine, methionine, arginine, phenylalanine, aspartic acid, proline, asparagine, serine, cysteine, threonine, glycine, tyrosine, glutamic acid, tryptophan, glutamine, valine, isoleucine, lysine, leucine, L-thioprolin, L-homoprolin, L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), L-2,3-dihydroindol-2-carboxylic acid, L-naphthylglycine, L-phenylglycine, L-4-phenylproline, O-benzyl tyrosine, omega-Z lysine, or omega-acetyl lysine; and Y' represents a pyrrolidide, a phosphonate or phosphinate derivative, or reduced peptide; or pharmaceutically acceptable salts thereof (US Patent Number 6,090,786 which disclosure is hereby incorporated by reference in its entirety).

Other preferred said antagonist is sulphostin (US Patent Number 6,214,340 which disclosure is hereby incorporated by reference in its entirety).

Other preferred said antagonist is N-(substituted glycy)-2-cyanopyrrolidine (US Patent Number 6,166,063). More preferred said N-(substituted glycy)-2-cyanopyrrolidine is selected from pyrrolidine, 1-[(3,5-dimethyl-1-adamantyl)amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[(3-ethyl-1-adamantyl)amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[(3-methoxy-1-adamantyl)amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[[[3-[(t-butylamino)carbonyl]oxy]-1-adamantyl]amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[[[3-[(4-methoxyphenyl)amino]-carbonyl]oxy]-1-adamantyl]amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[[[3-[(phenylamino)carbonyl]oxy]-1-adamantyl]amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[[[3-[(5-hydroxy-2-adamantyl)]amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[(3-acetyloxy-1-adamantyl)amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[[[3-[(diisopropyl)amino]carbonyl]oxy]-1-adamantyl]amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[[[3-[(cyclohexyl)amino]carbonyl]oxy]-1-adamantyl]amino]-acetyl]-2-cyano-, (S)-; pyrrolidine, 1-[(3-ethoxy-1-adamantyl)amino]-acetyl]-2-cyano-, (S)-; or, in each case, a pharmaceutically acceptable acid addition salt thereof (US Patent Number 6,166,063).

Other preferred said antagonist is tetrahydroisoquinoline 3-carboxamide derivative of formula ##STR1## (US Patent Number 6,172,081). More preferred is said derivative and pharmaceutically acceptable salts thereof wherein X is CH₂, S, O, or C(CH₃)₂; R₁ and R₂ are independently hydrogen, hydroxy, alkyl, alkoxy, aralkoxy, or halogen (US Patent Number 6,172,081).

Other preferred said antagonist is valine-pyrrolidide [Deacon (2001) Diabetes 50:1588-1597 which disclosure is hereby incorporated by reference in its entirety].

35 Multimers

The polypeptide fragments of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers

and multimers of the polypeptide fragments of the invention, their preparation, and compositions (preferably, pharmaceutical or physiologically acceptable compositions) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the OBG3 polypeptide fragments of the invention (including polypeptide fragments, variants, splice variants, and fusion proteins corresponding to these polypeptide fragments as described herein). These homomers may contain polypeptide fragments having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptide fragments having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptide fragments having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptide fragments having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptide fragments having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, corresponding to different proteins or polypeptide fragments thereof) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (*e.g.*, that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences, which interact in the native (*i.e.*, naturally occurring) polypeptide. In another instance, the covalent

associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteopontin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins, and have since been found in a variety of different proteins (Landschulz et al., (1988) Genes Dev. Jul;2(7):786-800). Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. FEBS Letters (1994) 344(2-3):191-5 and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention. In another example, proteins of the invention are associated by interactions between Flag® & polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C-terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, at least 30 techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (See, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

30

II. Pharmaceutical or Physiologically Acceptable Compositions of the Invention

The OBG3 and gOBG3 polypeptide fragments of the invention can be administered to non-human animals and/or humans, alone or in pharmaceutical or physiologically acceptable compositions where they are mixed with suitable carriers or excipient(s). The pharmaceutical or physiologically acceptable composition is then provided at a therapeutically effective dose. A therapeutically effective dose refers to that amount of OBG3 or gOBG3 fragment sufficient to result in prevention or amelioration of symptoms or physiological status of obesity-related diseases or disorders as determined

35

by the methods described herein. A therapeutically effective dose can also refer to the amount of OBG3 or gOBG3 fragment necessary for a reduction in weight or a prevention of an increase in weight or prevention of an increase in the rate of weight gain in persons desiring this affect for cosmetic reasons. A therapeutically effective dosage of an OBG3 or gOBG3 fragment of the invention is that
5 dosage that is adequate to promote weight loss or weight gain with continued periodic use or administration. Techniques for formulation and administration of OBG3 polypeptide fragments may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition.

Other diseases or disorders that OBG3 polypeptide fragments of the invention could be used to treat or prevent include, but are not limited to, obesity and obesity-related diseases and disorders such
10 as obesity, impaired glucose tolerance, insulin resistance, atherosclerosis, atheromatous disease, heart disease, hypertension, stroke, Syndrome X, Noninsulin Dependent Diabetes Mellitus (NIDDM, or Type II diabetes) and Insulin Dependent Diabetes Mellitus (IDDM or Type I diabetes). Diabetes-related complications to be treated by the methods of the invention include microangiopathic lesions, ocular lesions, retinopathy, neuropathy, and renal lesions. Heart disease includes, but is not limited
15 to, cardiac insufficiency, coronary insufficiency, and high blood pressure. Other obesity-related disorders to be treated by compounds of the invention include hyperlipidemia and hyperuricemia. Yet other obesity-related diseases or disorders of the invention include cachexia, wasting, AIDS-related weight loss, cancer-related weight loss, anorexia, and bulimia. The OBG3 or gOBG3 polypeptide fragments may also be used to enhance physical performance during work or exercise or
20 enhance a feeling of general well-being. Physical performance activities include walking, running, jumping, lifting and/or climbing.

The OBG3 or gOBG3 polypeptide fragments or antagonists thereof may also be used to treat dyslexia, attention-deficit disorder (ADD), attention-deficit/hyperactivity disorder (ADHD), and psychiatric disorders such as schizophrenia by modulating fatty acid metabolism, more specifically,
25 the production of certain long-chain polyunsaturated fatty acids.

It is expressly considered that the OBG3 or gOBG3 polypeptide fragments of the invention may be provided alone or in combination with other pharmaceutically or physiologically acceptable compounds. Other compounds useful for the treatment of obesity and other diseases and disorders are currently well-known in the art.

30 In a preferred embodiment, the OBG3 or gOBG3 polypeptide fragments are useful for, and used in, the treatment of insulin resistance and diabetes using methods described herein and known in the art. More particularly, a preferred embodiment relates to process for the therapeutic modification and regulation of glucose metabolism in an animal or human subject, which comprises administering to a subject in need of treatment (alternatively on a timed daily basis) an OBG or
35 OBG3 polypeptide fragment (or polynucleotide encoding said polypeptide) in dosage amount and for a period sufficient to reduce plasma glucose levels in said animal or human subject.

Further preferred embodiments relate to methods for the prophylaxis or treatment of diabetes comprising administering to a subject in need of treatment (alternatively on a timed daily basis) an OBG or OBG3 polypeptide fragment (or polynucleotide encoding said polypeptide) in dosage amount and for a period sufficient to reduce plasma glucose levels in said animal or human subject.

Routes of Administration.

The composition according to the present invention is preferably administered systemically. The administration can be carried out by methods familiar to a person skilled in the art, for example, intracisternally, intravenously, or peripherally. For the intracisternal or intravenous administration, OBG3 can be suspended, for example, in physiologic saline. However, infusion or bolus injections at regular time intervals are particularly preferred.

Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral, intrapulmonal, and intranasal administration. In addition, it may be desirable to introduce the pharmaceutical composition of the invention into the central nervous system by any suitable route, including intrathecal, e.g. intraventricular injection. Intraventricular injection may be facilitated by an intraventricular catheter, for example attached to a reservoir, such as an implantable port catheter system.

Furthermore, it may be desirable to administer the pharmaceutical compositions, which are used according to the invention, locally to the area in need of treatment. This may be achieved by, for example, and not by way of limitation, injection by means of a catheter or by means of an implant, said implant being of a porous, non-porous or gelatinous material, including membranes, such as sialastic membranes or fibers.

EXAMPLES

The following Examples are provided for illustrative purposes and not as a means of limitation. One of ordinary skill in the art would be able to design equivalent assays and methods based on the disclosure herein all of which form part of the instant invention.

It should be noted that the term full-length OBG3 polypeptide used throughout the specification is intended to encompass the protein homologs ACRP30 [Scherer, *et al.*, "A novel serum protein similar to C1q, produced exclusively in adipocytes"; J Biol Chem 270, 26746-26749 (1995)], AdipoQ [Hu, *et al.*, "AdipoQ is a novel adipose-specific gene dysregulated in obesity", J Biol Chem 271, 10697-10703 (1996)] and the human homolog APM1 [Maeda, *et al.*, "cDNA cloning and expression of a novel adipose specific collagen-like factor, APM1 (AdiPose Most abundant Gene transcript 1)", Biochem Biophys Res Commun 221, 286-289 (1996)] or GBP28 [Nakano, *et al.*, "Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma", J Biochem (Tokyo) 120, 803-812 (1996)]. OBG3 is also intended to encompass other homologs.

EXAMPLE 1: Demyelination in "Gottingen Mini Pigs"

Lesion:

An experimental model of demyelination has been established in the female adult "Gottingen Mini Pig" (age: 10-14 months, weight 25-30 kg) by stereotaxic injection of lysolecithin (LL) at multiple sites into periventricular subcortical white matter of the brain (usually 2-3 injection sites located in one hemisphere; 5 ul of 1% LL in 0.9% saline per lesion infused over a period of 15 min.). This infusion causes a rapid reduction of myeline sheaths within the diffusion area of the detergent (Blakemore, W.F., Neuropathol. Appl. Neurobiol. 4 (1978) 47-59).

OBG3 application:

Immediately after LL-application, a stainless steel needle is implanted in the left ventricle space and affixed with an ionomeric bonding bone cement and an osmotic pump (200 ul volume, infusion rate is connected with the needle and implanted subcutaneously, or a catheter system) is implanted either into the lateral ventricle of the brain or in the subarachnoidal space of the lumer spinal cord.

Ways of application:

1. Chornic infusion of OBG3 via Alzet pump directly intracerebral, beyond the blood brain barrier:

- application interval: 7-20 days
- concentration of OBG3: 0.4mg/ml, dissolved in PBS, pH 7.2-7.4
- dosages: 0.5 ug/h corresponding to 1.2-4 ug/kg/interval

2. Pulsative injections of OBG3:

After fixation of the catheter with bone cement, the intrathecal catheter is connected with a subcutaneous drug delivery system that is implanted subcutaneously in the upper back region. OBG3 (dissolved in phosphate buffer saline) injected every 2nd day through the skin into the port, starting 2 days after initial LL lesions, by single bolus injections into the port at a dose of 0.05-5 ug/kg body weight (3-350 ug/injection). 3-5 injections were carried out into the cerebrospinal fluid within a period of 6-12 days after LL-induced demyelination.

Controls:

Controls are carried out by replacement of OBG3 with an equal dose of Cytochrome C applied in the same ways and time intervals/

Evaluation of OBG3 effects:

At the end of the OBG3 (control, respectively) application period, the experimental animals are sacrificed, the brain removed and prepared for histological examination: the areas of interest were studied with routine histological (H.E. staining, Luxol Fast Blue staining), immunocytochemical (myeline basic protein-MBP) and MRI-analysis.

ADDITIONAL REFERENCES

1. Shapiro, L. & Scherer, P. E., "The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor", *Curr Biol* 8, 335-338 (1998).
- 5 2. Kishore, U. & Reid, K. B., "Modular organization of proteins containing C1q-like globular domain", *Immunopharmacology* 42, 15-21 (1999).
3. Kavety, B. & Morgan, J. I., "Characterization of transcript processing of the gene encoding precerebellin-1", *Brain Res Mol Brain Res* 63, 98-104 (1998).
4. Satoh, F. et al., "Cerebellin and cerebellin mRNA in the human brain, adrenal glands and the
10 tumour tissues of adrenal tumour, ganglioneuroblastoma and neuroblastoma", *J Endocrinol* 154, 27-34 (1997).
5. Mazzocchi, G. et al., "Cerebellin enhances in vitro secretory activity of human adrenal gland", *J Clin Endocrinol Metab* 84, 632-635 (1999).
6. Kondo, N. & Kondo, J., "Identification of novel blood proteins specific for mammalian
15 hibernation", *J Biol Chem* 267, 473-478 (1992).
7. Takamatsu, N., Ohba, K., Kondo, J., Kondo, N. & Shiba, T., "Hibernation-associated gene regulation of plasma proteins with a collagen-like domain in mammalian hibernators", *Mol Cell Biol* 13, 1516-1521 (1993).
8. Spiegelman, B. M. & Hotamisligil, G. S., "Through thick and thin: wasting, obesity, and
20 TNF alpha", *Cell* 73, 625-627 (1993).
9. Saito, K. et al., "Regulation of gelatin-binding protein 28 (GBP28) gene expression by C/EBP", *Biol Pharm Bull* 22, 1158-1162 (1999).
10. Takamatsu, N. et al., "Expression of multiple alpha1-antitrypsin-like genes in hibernating species of the squirrel family", *Gene* 204, 127-132 (1997).
- 25 11. Ross, S. R., Graves, R. A. & Spiegelman, B. M., "Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity", *Genes Dev* 7, 1318-1324 (1993).
12. Moitra, J. et al., "Life without white fat: a transgenic mouse", *Genes Dev* 12, 3168-3181 (1998).
13. Peters, S. J., Dyck, D. J., Bonen, A. & Spriet, L. L., "Effects of epinephrine on lipid
30 metabolism in resting skeletal muscle", *Am J Physiol* 275, E300-309 (1998).
14. Rigotti, A., Acton, S. L. & Krieger, M., "The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids", *J Biol Chem* 270, 16221-16224 (1995).
15. Hirsch, D., Stahl, A. & Lodish, H. F., "A family of fatty acid transporters conserved from mycobacterium to man", *Proc Natl Acad Sci U S A* 95, 8625-8629 (1998).
- 35 16. Hotamisligil, G. S. et al., "IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance", *Science* 271, 665-668 (1996).

17. Peraldi, P. & Spiegelman, B., "TNF-alpha and insulin resistance: summary and future prospects", *Mol Cell Biochem* 182, 169-175 (1998).
18. Kirchgessner, T. G., Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S., "Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes", *J Clin Invest* 100, 2777-2782 (1997).
19. Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S., "Protection from obesity-induced insulin resistance in mice lacking TNF- alpha function", *Nature* 389, 610-614 (1997).
20. Jensen, D. R. et al., "Prevention of diet-induced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase", *Am J Physiol* 273, R683-689 (1997).
21. Levak-Frank, S. et al., "Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice", *J Clin Invest* 96, 976-986 (1995).
22. Scheja, L. et al., "Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice", *Diabetes* 48, 1987-1994 (1999).
23. Griffin, M. E. et al., "Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade", *Diabetes* 48, 1270-1274 (1999).
24. Dresner, A. et al., "Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity", *J Clin Invest* 103, 253-259 (1999).
25. Kelley, D. E., Goodpaster, B., Wing, R. R. & Simoneau, J. A., "Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss", *Am J Physiol* 277, E1130-1141 (1999).
26. Roden, M. et al., "Mechanism of free fatty acid-induced insulin resistance in humans", *J Clin Invest* 97, 2859-2865 (1996).
27. Deacon, C. F. et al., "Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs", *Diabetes* 50, 1588-1597 (2001).

CLAIMS

What is claimed is:

- 5 1. A method of increasing the rate of regeneration of myelin sheaths of axons comprising the step of contacting an oligodendrocyte progenitor cell with a composition comprising a polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 6 or a biologically active fragment thereof.
2. A method of increasing the rate of cellular division of oligodendrocyte progenitor
10 cells in which said oligodendrocyte progenitor cells are contacted with a composition comprising a polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 6 or a biologically active fragment thereof.
3. A method of increasing the rate of migration of oligodendrocyte progenitor cells from the germinal centers to demyelinated axons in the CNS in which said oligodendrocyte
15 progenitor cells are contacted with a composition comprising a polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 6 or a biologically active fragment thereof.
4. A method of inducing oligodendrocyte progenitor cells to differentiate into mature dendrocytic cells at sites of demyelination in axons in the CNS in which said oligodendrocyte progenitor cells are contacted with a composition comprising a polypeptide sequence comprising the
20 amino acid sequence of SEQ ID NO: 6 or a biologically active fragment thereof.
5. The method of any one of claims 1-4, wherein said method is used to treat multiple sclerosis.
6. The method of any one of claims 1-4, wherein said method is used to treat hereditary leukodystrophies selected from the group consisting of metachromatic leukodystrophy,
25 Refsum's disease, adrenoleukodystrophy, Krabbe's disease, phenylketonuria, Canavan disease, Pelizaeus-Merzbacher disease, and Alexander's disease.
7. The method of any one of claims 1-4, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 84-244, 85-244, 101 to 244, 102-244, or 103-244 of SEQ ID NO:6.
- 30 8. The method of any one of claims 1-4, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 166-193, amino acids 166-176, or amino acids 167-176 of SEQ ID NO: 6 or a biologically active fragment thereof.
9. The use of a pharmaceutical composition for the treatment of diseases in which demyelination of nerve fibers occurs, comprising an amino acid sequence selected from the group
35 consisting of amino acids 84-244, 85-244, 101 to 244, 102-244, 103-244, 166-193, 166-176, or 167-176 of SEQ ID NO:6 or a biologically active fragment thereof.
10. A method for the production of a pharmaceutical composition for use in the treatment of disease in which demyelination of nerve fibers occurs, characterized in that an amino

acid sequence selected from the group consisting of amino acids 84-244, 85-244, 101 to 244, 102-244, 103-244, 166-193, 166-176, or 167-176 of SEQ ID NO:6 or a biologically active fragment thereof is used as an essential component of the composition.

11. The method of any one of claims 1-4, 7 or 8, wherein said polypeptide is
5 administered to an individual in need thereof.

SEQUENCE LISTING

<110> GENSET

<120> Use of OBG3 for Promoting Central Nervous System Remyelination

<130> 161.WO1

<150> 60/332,119

<151> 2001-11-21

<160> 7

<170> Patent.pm

<210> 1

<211> 1152

<212> DNA

<213> mus musculus

<400> 1

```

gaattcggca cgaggg atg cta ctg ttg caa gct ctc ctg ttc ctc tta atc      52
      Met Leu Leu Leu Gln Ala Leu Leu Phe Leu Leu Ile
              1              5              10
ctg ccc agt cat gcc gaa gat gac gtt act aca act gaa gag cta gct      100
Leu Pro Ser His Ala Glu Asp Asp Val Thr Thr Thr Glu Glu Leu Ala
              15              20              25
cct gct ttg gtc cct cca ccc aag gga act tgt gca ggt tgg atg gca      148
Pro Ala Leu Val Pro Pro Pro Lys Gly Thr Cys Ala Gly Trp Met Ala
              30              35              40
ggc atc cca gga cat tct ggc cac aat ggc aca cca ggc cgt gat ggc      196
Gly Ile Pro Gly His Ser Gly His Asn Gly Thr Pro Gly Arg Asp Gly
              45              50              55              60
aga gat ggc act cct gga gag aag gga gag aaa gga gat tca ggt ctt      244
Arg Asp Gly Thr Pro Gly Glu Lys Gly Glu Lys Gly Asp Ser Gly Leu
              65              70              75
ctt ggt cct aag ggt gag aca gga gat gtt gga atg aca gga gct gaa      292
Leu Gly Pro Lys Gly Glu Thr Gly Asp Val Gly Met Thr Gly Ala Glu
              80              85              90
ggg cct cgg ggc ttc ccc gga acc cct ggc agg aaa gga gag cct gga      340
Gly Pro Arg Gly Phe Pro Gly Thr Pro Gly Arg Lys Gly Glu Pro Gly
              95              100              105
gaa gcc gct tat gtg tat cgc tca ggc ttc agt gtg ggg ctg gag acc      388
Glu Ala Ala Tyr Val Tyr Arg Ser Gly Phe Ser Val Gly Leu Glu Thr
              110              115              120
cgc gtc act gtt ccc aat gta ccc att cgc ttt act aag atc ttc tac      436
Arg Val Thr Val Pro Asn Val Pro Ile Arg Phe Thr Lys Ile Phe Tyr
              125              130              135              140
aac caa cag aat cat tat gac aac agc act ggc aag ttc tac tgc aac      484
Asn Gln Gln Asn His Tyr Asp Asn Ser Thr Gly Lys Phe Tyr Cys Asn
              145              150              155
att ccg gga ctc tac tac ttc tct tac cac atc acg gtg tac atg aaa      532
Ile Pro Gly Leu Tyr Tyr Phe Ser Tyr His Ile Thr Val Tyr Met Lys
              160              165              170
gat gtg aag gtg agc ctc ttc aag aag gac aag gcc gtt ctc ttc acc      580
Asp Val Lys Val Ser Leu Phe Lys Lys Asp Lys Ala Val Leu Phe Thr
              175              180              185
tac gac cag tat cag gaa aag aat gtg gac cag gcc tct ggc tct gtg      628
Tyr Asp Gln Tyr Gln Glu Lys Asn Val Asp Gln Ala Ser Gly Ser Val
              190              195              200
ctc ctc cat ctg gag gtg gga gac caa gtc tgg ctc cag gtg tat ggg      676
Leu Leu His Leu Glu Val Gly Asp Gln Val Trp Leu Gln Val Tyr Gly
              205              210              215              220

```

2

```

gat ggg gac cac aat gga ctc tat gca gat aac gtc aac gac tct aca      724
Asp Gly Asp His Asn Gly Leu Tyr Ala Asp Asn Val Asn Asp Ser Thr
                225                230                235
ttt act ggc ttt ctt ctc ttc cat gat acc aac tga ctgcaactac      770
Phe Thr Gly Phe Leu Leu Phe His Asp Thr Asn *
                240                245
tcatagccca tacaccagga gaatcatgga acgtcgacac actttcagct tagtttgaga      830
gattgatttt attgcttagt ttgagagtcc tgagtattat ccacacgtgt actcacttgt      890
tcattaaacg actttataaa aaataatttg tggttcctagt ccagaaaaaa aggcactccc      950
tggtctccac gactcttaca tggtagcaat aacagaatga aaatcacatt tggtatgggg      1010
gcttcacaat attcgcatga ctgtctggaa gtagaccatg ctatttttct gctcactgta      1070
cacaaatatt gttcacataa accctataat gtaaatatga aatacagtga ttatcttctc      1130
aaaaaaaact cgtgccgaat tc      1152

```

<210> 2

<211> 247

<212> PRT

<213> mus musculus

<400> 2

```

Met Leu Leu Leu Gln Ala Leu Leu Phe Leu Leu Ile Leu Pro Ser His
1          5          10          15
Ala Glu Asp Asp Val Thr Thr Thr Glu Glu Leu Ala Pro Ala Leu Val
          20          25          30
Pro Pro Pro Lys Gly Thr Cys Ala Gly Trp Met Ala Gly Ile Pro Gly
          35          40          45
His Ser Gly His Asn Gly Thr Pro Gly Arg Asp Gly Arg Asp Gly Thr
          50          55          60
Pro Gly Glu Lys Gly Glu Lys Gly Asp Ser Gly Leu Leu Gly Pro Lys
          65          70          75          80
Gly Glu Thr Gly Asp Val Gly Met Thr Gly Ala Glu Gly Pro Arg Gly
          85          90          95
Phe Pro Gly Thr Pro Gly Arg Lys Gly Glu Pro Gly Glu Ala Ala Tyr
          100          105          110
Val Tyr Arg Ser Gly Phe Ser Val Gly Leu Glu Thr Arg Val Thr Val
          115          120          125
Pro Asn Val Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn
          130          135          140
His Tyr Asp Asn Ser Thr Gly Lys Phe Tyr Cys Asn Ile Pro Gly Leu
          145          150          155          160
Tyr Tyr Phe Ser Tyr His Ile Thr Val Tyr Met Lys Asp Val Lys Val
          165          170          175
Ser Leu Phe Lys Lys Asp Lys Ala Val Leu Phe Thr Tyr Asp Gln Tyr
          180          185          190
Gln Glu Lys Asn Val Asp Gln Ala Ser Gly Ser Val Leu Leu His Leu
          195          200          205
Glu Val Gly Asp Gln Val Trp Leu Gln Val Tyr Gly Asp Gly Asp His
          210          215          220
Asn Gly Leu Tyr Ala Asp Asn Val Asn Asp Ser Thr Phe Thr Gly Phe
          225          230          235          240
Leu Leu Phe His Asp Thr Asn
          245

```

<210> 3

<211> 1276

<212> DNA

<213> mus musculus

<400> 3

```

ctctaaagat tgtcagtgga tctgacgaca ccaaaagggc tcagg atg cta ctg ttg      57
                               Met Leu Leu Leu
                               1
caa gct ctc ctg ttc ctc tta atc ctg ccc agt cat gcc gaa gat gac      105

```

Gln	Ala	Leu	Leu	Phe	Leu	Leu	Ile	Leu	Pro	Ser	His	Ala	Glu	Asp	Asp	
5					10					15					20	
gtt	act	aca	act	gaa	gag	cta	gct	cct	gct	ttg	gtc	cct	cca	ccc	aag	153
Val	Thr	Thr	Thr		Glu	Leu	Ala	Pro	Ala	Leu	Val	Pro	Pro	Pro	Lys	
				25					30					35		
gga	act	tgt	gca	ggg	tgg	atg	gca	ggc	atc	cca	gga	cat	cct	ggc	cac	201
Gly	Thr	Cys	Ala	Gly	Trp	Met	Ala	Gly	Ile	Pro	Gly	His	Pro	Gly	His	
			40					45					50			
aat	ggc	aca	cca	ggc	cgt	gat	ggc	aga	gat	ggc	act	cct	gga	gag	aag	249
Asn	Gly	Thr	Pro	Gly	Arg	Asp	Gly	Arg	Asp	Gly	Thr	Pro	Gly	Glu	Lys	
			55				60					65				
gga	gag	aaa	gga	gat	gca	ggg	ctt	ctt	ggg	cct	aag	ggg	gag	aca	gga	297
Gly	Glu	Lys	Gly	Asp	Ala	Gly	Leu	Leu	Gly	Pro	Lys	Gly	Glu	Thr	Gly	
	70					75					80					
gat	gtt	gga	atg	aca	gga	gct	gaa	ggg	cca	cgg	ggc	ttc	ccc	gga	acc	345
Asp	Val	Gly	Met	Thr	Gly	Ala	Glu	Gly	Pro	Arg	Gly	Phe	Pro	Gly	Thr	
85					90					95					100	
cct	ggc	agg	aaa	gga	gag	cct	gga	gaa	gcc	gct	tat	atg	tat	cgc	tca	393
Pro	Gly	Arg	Lys	Gly	Glu	Pro	Gly	Glu	Ala	Ala	Tyr	Met	Tyr	Arg	Ser	
				105					110					115		
gcg	ttc	agt	gtg	ggg	ctg	gag	acc	cgc	gtc	act	gtt	ccc	aat	gta	ccc	441
Ala	Phe	Ser	Val	Gly	Leu	Glu	Thr	Arg	Val	Thr	Val	Pro	Asn	Val	Pro	
			120						125				130			
att	cgc	ttt	act	aag	atc	ttc	tac	aac	caa	cag	aat	cat	tat	gac	ggc	489
Ile	Arg	Phe	Thr	Lys	Ile	Phe	Tyr	Asn	Gln	Gln	Asn	His	Tyr	Asp	Gly	
			135				140					145				
agc	act	ggc	aag	ttc	tac	tgc	aac	att	ccg	gga	ctc	tac	tac	ttc	tct	537
Ser	Thr	Gly	Lys	Phe	Tyr	Cys	Asn	Ile	Pro	Gly	Leu	Tyr	Tyr	Phe	Ser	
	150					155					160					
tac	cac	atc	acg	gtg	tac	atg	aaa	gat	gtg	aag	gtg	agc	ctc	ttc	aag	585
Tyr	His	Ile	Thr	Val	Tyr	Met	Lys	Asp	Val	Lys	Val	Ser	Leu	Phe	Lys	
165					170					175				180		
aag	gac	aag	gcc	gtt	ctc	ttc	acc	tac	gac	cag	tat	cag	gaa	aag	aat	633
Lys	Asp	Lys	Ala	Val	Leu	Phe	Thr	Tyr	Asp	Gln	Tyr	Gln	Glu	Lys	Asn	
				185					190				195			
gtg	gac	cag	gcc	tct	ggc	tct	gtg	ctc	ctc	cat	ctg	gag	gtg	gga	gac	681
Val	Asp	Gln	Ala	Ser	Gly	Ser	Val	Leu	His	Leu	Glu	Val	Gly	Asp		
			200					205				210				
caa	gtc	tgg	ctc	cag	gtg	tat	ggg	gat	ggg	gac	cac	aat	gga	ctc	tat	729
Gln	Val	Trp	Leu	Gln	Val	Tyr	Gly	Asp	Gly	Asp	His	Asn	Gly	Leu	Tyr	
			215				220					225				
gca	gat	aac	gtc	aac	gac	tct	aca	ttt	act	ggc	ttt	ctt	ctc	tac	cat	777
Ala	Asp	Asn	Val	Asn	Asp	Ser	Thr	Phe	Thr	Gly	Phe	Leu	Leu	Tyr	His	
	230					235					240					
gat	acc	aac	tga	ctg	caactac	ccatagccca	tacaccagga	gaatcatgga								829
Asp	Thr	Asn	*													
245																
acagtcgaca	cacttttcagc	ttagtttgag	agattgattt	tattgcttag	tttgagagtc											889
ctgagtatta	ttcacacgtg	tactcacttg	ttcattaaac	gactttataa	aaaataattt											949
gtgttcctag	ttcagaaaaa	aaggcactcc	ctgggtctcca	cgactcttac	atggttagcaa											1009
taacagaatg	aaaatcacat	ttggtatggg	ggcttcacaa	tattcgcatg	actgtotgga											1069
agtagaccat	gctatttttc	tgctcactgt	acacaaatat	tgttcacata	aacctataa											1129
tgtaaatatg	aaatacagtg	attactcttc	tcacaggctg	agtgtatgaa	tgtctaaaga											1189
cccataagta	ttaaagtggg	agggataaat	tggaaaaaaa	aaaaaaaaaa	aagaaaaact											1249
ttagagcaca	ctggcgcccg	ttactag														1276

<210> 4

<211> 247

<212> PRT

<213> mus musculus

<400> 4

Met Leu Leu Leu Gln Ala Leu Leu Phe Leu Leu Ile Leu Pro Ser His

4

1	5	10	15
Ala Glu Asp Asp Val Thr Thr Thr	Glu Leu Ala Pro Ala Leu Val		
20	25	30	
Pro Pro Pro Lys Gly Thr Cys Ala	Gly Trp Met Ala Gly Ile Pro Gly		
35	40	45	
His Pro Gly His Asn Gly Thr Pro	Gly Arg Asp Gly Arg Asp Gly Thr		
50	55	60	
Pro Gly Glu Lys Gly Glu Lys Gly	Asp Ala Gly Leu Leu Gly Pro Lys		
65	70	75	80
Gly Glu Thr Gly Asp Val Gly Met	Thr Gly Ala Glu Gly Pro Arg Gly		
85	90	95	
Phe Pro Gly Thr Pro Gly Arg Lys	Gly Glu Pro Gly Glu Ala Ala Tyr		
100	105	110	
Met Tyr Arg Ser Ala Phe Ser Val	Gly Leu Glu Thr Arg Val Thr Val		
115	120	125	
Pro Asn Val Pro Ile Arg Phe Thr	Lys Ile Phe Tyr Asn Gln Gln Asn		
130	135	140	
His Tyr Asp Gly Ser Thr Gly Lys	Phe Tyr Cys Asn Ile Pro Gly Leu		
145	150	155	160
Tyr Tyr Phe Ser Tyr His Ile Thr	Val Tyr Met Lys Asp Val Lys Val		
165	170	175	
Ser Leu Phe Lys Lys Asp Lys Ala	Val Leu Phe Thr Tyr Asp Gln Tyr		
180	185	190	
Gln Glu Lys Asn Val Asp Gln Ala	Ser Gly Ser Val Leu Leu His Leu		
195	200	205	
Glu Val Gly Asp Gln Val Trp Leu	Gln Val Tyr Gly Asp Gly Asp His		
210	215	220	
Asn Gly Leu Tyr Ala Asp Asn Val	Asn Asp Ser Thr Phe Thr Gly Phe		
225	230	235	240
Leu Leu Tyr His Asp Thr Asn			
245			

<210> 5

<211> 4517

<212> DNA

<213> Homo sapiens

<400> 5

ctgattccat accagagggg ctcagg atg ctg ttg ctg gga gct gtt cta ctg	53
Met Leu Leu Leu Gly Ala Val Leu Leu	
1 5	
cta tta gct ctg ccc ggg cat gac cag gaa acc acg act caa ggg ccc	101
Leu Leu Ala Leu Pro Gly His Asp Gln Glu Thr Thr Thr Gln Gly Pro	
10 15 20 25	
gga gtc ctg ctt ccc ctg ccc aag ggg gcc tgc aca ggt tgg atg gcg	149
Gly Val Leu Leu Pro Leu Pro Lys Gly Ala Cys Thr Gly Trp Met Ala	
30 35 40	
ggc atc cca ggg cat ccg ggc cat aat ggg gcc cca ggc cgt gat ggc	197
Gly Ile Pro Gly His Pro Gly His Asn Gly Ala Pro Gly Arg Asp Gly	
45 50 55	
aga gat ggc acc cct ggt gag aag ggt gag aaa gga gat cca ggt ctt	245
Arg Asp Gly Thr Pro Gly Glu Lys Gly Glu Lys Gly Asp Pro Gly Leu	
60 65 70	
att ggt cct aag gga gac atc ggt gaa acc gga gta ccc ggg gct gaa	293
Ile Gly Pro Lys Gly Asp Ile Gly Glu Thr Gly Val Pro Gly Ala Glu	
75 80 85	
ggt ccc cga ggc ttt ccg gga atc caa ggc agg aaa gga gaa cct gga	341
Gly Pro Arg Gly Phe Pro Gly Ile Gln Gly Arg Lys Gly Glu Pro Gly	
90 95 100 105	
gaa ggt gcc tat gta tac cgc tca gca ttc agt gtg gga ttg gag act	389
Glu Gly Ala Tyr Val Tyr Arg Ser Ala Phe Ser Val Gly Leu Glu Thr	
110 115 120	
tac gtt act atc ccc aac atg ccc att cgc ttt acc aag atc ttc tac	437


```

tggttttctgg tgatgccc aa agaggagaga ggaagctctc tttcccagat gccccagcaa 3231
gtgtaacctt gcatctcatt gctctggctg agttgtgtgc ctgtttctga ccaatcactg 3291
agtcaggagg atgaaatatt catattgact taattgcagc ttaagttagg ggtatgtaga 3351
ggatattttcc ctaaaagcaa attgggacac tgttatcaga aataggagag tggatgatat 3411
atgcaaaata atacctgtcc acaacaaact cttaatgctg tgtttgagct ttcattgagtt 3471
tcccagagag acatagctgg aaaattccta ttgattttct ctaaaatttc aacaagtagc 3531
taaagtctgg ctatgctcac agtctcacat ctgggtggggg tgggctcctt acagaacacg 3591
ctttcacagt taccctaaac tctctggggc agggttattc ctttgtggaa ccagaggcac 3651
agagacagtc aactgaggcc caacagaggc ctgagagaaa ctgagggtcaa gatttcagga 3711
ttaatgggtcc tgtgatgctt tgaagtacaa ttgtggattt gtccaattct ctttagttct 3771
gtcagctttt gcttcataata ttttagcgct ctattattag atatatacat gtttagtatt 3831
atgtottatt ggtgcattta ctctcttatt attatgtaat gtcttctttt atctgtgata 3891
attttctgtg tcttgaagtc tactttgtct aaaaataaca tacgcactca acttctttt 3951
ctttcttctt tcttttcttt ctctcttctt ttctttctct ctctctcttt ccttcttctc 4011
ttctctcttt tctctctctc tctctctctc tctcttttct tgacagactc tegtctgtg 4071
gccctggctg gagttcagtg gtgtgatctt ggctcactgc tactcttacc atgagcaatt 4131
ctcctgcctc agcctcccaa gtagctggaa ctacaggctc atgccactgc gccagctaa 4191
tttttgtatt tttcgtagag acgggggttt accacattcg tcagggttgg ttcaaactcc 4251
tgactttgtg atccaccgc ctggcctcc caaagtgtg ggattacagg catgagccat 4311
cacacctggc caactttctt ttgattagtg tttttgtgg atattctttt ccatcatgtt 4371
actttaaata tatctatatt attgtattta aaatgtgtt cttacagact gcatgtagtt 4431
gggtataatt tttatccagt ctaaaaatat ctgtctttta attggtgttt agacaattta 4491
tatttaataa aatggtggaa tttaaa 4517

```

<210> 6

<211> 244

<212> PRT

<213> Homo sapiens

<400> 6

```

Met Leu Leu Leu Gly Ala Val Leu Leu Leu Leu Ala Leu Pro Gly His
1          5          10          15
Asp Gln Glu Thr Thr Thr Gln Gly Pro Gly Val Leu Leu Pro Leu Pro
20          25          30
Lys Gly Ala Cys Thr Gly Trp Met Ala Gly Ile Pro Gly His Pro Gly
35          40          45
His Asn Gly Ala Pro Gly Arg Asp Gly Arg Asp Gly Thr Pro Gly Glu
50          55          60
Lys Gly Glu Lys Gly Asp Pro Gly Leu Ile Gly Pro Lys Gly Asp Ile
65          70          75          80
Gly Glu Thr Gly Val Pro Gly Ala Glu Gly Pro Arg Gly Phe Pro Gly
85          90          95
Ile Gln Gly Arg Lys Gly Glu Pro Gly Glu Gly Ala Tyr Val Tyr Arg
100         105         110
Ser Ala Phe Ser Val Gly Leu Glu Thr Tyr Val Thr Ile Pro Asn Met
115         120         125
Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn His Tyr Asp
130         135         140
Gly Ser Thr Gly Lys Phe His Cys Asn Ile Pro Gly Leu Tyr Tyr Phe
145         150         155         160
Ala Tyr His Ile Thr Val Tyr Met Lys Asp Val Lys Val Ser Leu Phe
165         170         175
Lys Lys Asp Lys Ala Met Leu Phe Thr Tyr Asp Gln Tyr Gln Glu Asn
180         185         190
Asn Val Asp Gln Ala Ser Gly Ser Val Leu Leu His Leu Glu Val Gly
195         200         205
Asp Gln Val Trp Leu Gln Val Tyr Gly Glu Gly Glu Arg Asn Gly Leu
210         215         220
Tyr Ala Asp Asn Asp Asn Asp Ser Thr Phe Thr Gly Phe Leu Leu Tyr
225         230         235         240
His Asp Thr Asn

```

<210> 7

<211> 20966
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> 1..4811
<223> 5' regulatory region

<220>
<221> exon
<222> 4812..4851
<223> exon 1

<220>
<221> exon
<222> 15144..15365
<223> exon 2

<220>
<221> exon
<222> 16277..20559
<223> exon 3

<220>
<221> misc_feature
<222> 20560..20966
<223> 3' regulatory region

<220>
<221> allele
<222> 3787
<223> 9-27-261 : polymorphic base G or C

<220>
<221> allele
<222> 11118
<223> 99-14387-129 : polymorphic base A or C

<220>
<221> allele
<222> 15120
<223> 9-12-48 : polymorphic base C or T

<220>
<221> allele
<222> 15196
<223> 9-12-124 : polymorphic base G or T

<220>
<221> allele
<222> 15427
<223> 9-12-355 : polymorphic base G or T

<220>
<221> allele
<222> 15500
<223> 9-12-428 : polymorphic base A or G

<220>
<221> allele
<222> 15863
<223> 99-14405-105 : polymorphic base A or G

<220>
<221> allele
<222> 17170
<223> 9-16-189 : polymorphic base deletion of A

<220>
<221> primer_bind
<222> 3528..3545
<223> 9-27.pu

<220>
<221> primer_bind
<222> 3928..3946
<223> 9-27.rp complement

<220>
<221> primer_bind
<222> 10990..11008
<223> 99-14387.pu

<220>
<221> primer_bind
<222> 11423..11442
<223> 99-14387.rp complement

<220>
<221> primer_bind
<222> 15073..15092
<223> 9-12.pu

<220>
<221> primer_bind
<222> 15503..15520
<223> 9-12.rp complement

<220>
<221> primer_bind
<222> 15759..15776
<223> 99-14405.pu

<220>
<221> primer_bind
<222> 16191..16211
<223> 99-14405.rp complement

<220>
<221> primer_bind
<222> 16982..17001
<223> 9-16.pu

<220>
<221> primer_bind
<222> 17384..17402
<223> 9-16.rp complement

<220>
<221> misc_binding
<222> 3775..3799
<223> 9-27-261.probe

<220>
<221> misc_binding

<222> 11106..11130
<223> 99-14387-129.probe

<220>
<221> misc_binding
<222> 15108..15132
<223> 9-12-48.probe

<220>
<221> misc_binding
<222> 15184..15208
<223> 9-12-124.probe

<220>
<221> misc_binding
<222> 15415..15439
<223> 9-12-355.probe

<220>
<221> misc_binding
<222> 15488..15512
<223> 9-12-428.probe

<220>
<221> misc_binding
<222> 15851..15875
<223> 99-14405-105.probe

<220>
<221> misc_binding
<222> 17158..17182
<223> 9-16-189.probe

<220>
<221> primer_bind
<222> 3768..3786
<223> 9-27-261.mis

<220>
<221> primer_bind
<222> 3788..3806
<223> 9-27-261.mis complement

<220>
<221> primer_bind
<222> 11099..11117
<223> 99-14387-129.mis

<220>
<221> primer_bind
<222> 11119..11137
<223> 99-14387-129.mis complement

<220>
<221> primer_bind
<222> 15101..15119
<223> 9-12-48.mis

<220>
<221> primer_bind
<222> 15121..15139
<223> 9-12-48.mis complement

<220>
 <221> primer_bind
 <222> 15177..15195
 <223> 9-12-124.mis

<220>
 <221> primer_bind
 <222> 15197..15215
 <223> 9-12-124.mis complement

<220>
 <221> primer_bind
 <222> 15408..15426
 <223> 9-12-355.mis

<220>
 <221> primer_bind
 <222> 15428..15446
 <223> 9-12-355.mis complement

<220>
 <221> primer_bind
 <222> 15481..15499
 <223> 9-12-428.mis

<220>
 <221> primer_bind
 <222> 15501..15519
 <223> 9-12-428.mis complement

<220>
 <221> primer_bind
 <222> 15844..15862
 <223> 99-14405-105.mis

<220>
 <221> primer_bind
 <222> 15864..15882
 <223> 99-14405-105.mis complement

<220>
 <221> primer_bind
 <222> 17151..17169
 <223> 9-16-189.mis

<220>
 <221> primer_bind
 <222> 17171..17189
 <223> 9-16-189.mis complement

<400> 7
 gctgatctgc tgcctcagcc ttcccaaagt gctgtaattt attaggcata agccactgtg 60
 cctgcctagt gttgtacatt ctgtgggttt tgacaattgt atgcatctac atgtatgtac 120
 catttatagt attcctgttt ttaatttttag ccattctagt aggcattgtg tgatatctca 180
 tgggtgatttt aatttgcggt tccgtaatgg ttaataatgc tgaacatctt tgcatgtgct 240
 tgtttgtcat ttgtgtttcc tacttggtga aataattggt catgtccttt gtccattttc 300
 taattgaatt tttttttacc atttagtttt gagatttctt tatacaatct agatccaaat 360
 ctcttgtctc aaatatggtt tgcaaataca ttcttctaatt tcatatatatt ccttttcctc 420
 ctcttaacag gatgtttcac agagcaaaag ttttagtttt gttgaaatct cacttttcat 480
 ttttttcttt agtggattgt gcttttggtt tcatatgtaa gaactcttca ctggccctag 540
 atccttgat tgggtttccta agattgccat agcaaatcac catgaactta gtgacaaaaa 600
 gacagaaatt tatttttact tcctactgtg ggcagactag acgttaatta ttttcatgta 660
 tgctcattcc tatgacatct ttctgatata ataattatag ttattcttaa gcttcaccct 720

tttttctatt	agctttgtta	ccttgggtgt	cactttttct	tttttgacat	tgtgacctat	780
gccagatcat	gtctgttagt	acttagccct	ccattcacct	ctccataatc	ccttttgtat	840
tcctggagct	tgatgcctga	aatgacacat	cctacattcc	tttgccagat	gggtaccagt	900
tagcttgtgc	acatgggaga	caaccgtgaa	aagactgaag	tggggaagaa	gggaggagct	960
gttgtgtttc	agttagcgcc	cctggcagtg	gcggtgacag	tggctcctgt	tcagtggcaa	1020
tggtaggaca	gctagcaaga	catgcagtaa	gcgcaggctc	ataggctatg	gtccaggagc	1080
agtcaccgat	tcctggtctt	taggcaatat	catctccctt	tgcttctcca	gcctttctaa	1140
aattattgta	ccttgactag	tacaattttt	tagtattggg	ggtagtccaa	ggacacaggc	1200
tttaaaaagt	atgaattcag	ggttgcctac	ctgcattgac	tgcgcttgaa	tcatgatggc	1260
cttctggtcg	gtggcaggag	gtgacagtcc	aaatcatgca	gtagcaaacc	agatacttaa	1320
attatcatct	gagatacttc	agaagtacag	ccgtagccat	accttcagaa	gagataaaga	1380
aatgttctcc	tggccaggcg	cggtaggtca	cgcctgtcat	tccagcactt	tgggaggccg	1440
agggggtgga	tcacctgagg	tcgggagttc	gagaccagcc	tgaccaacat	ggggaaaccc	1500
tgtctctact	aaaaatacaa	aattagcggg	gcgtgggtggc	acatgcccat	aatcccagct	1560
actcgggagg	ctaaggcagg	ataatcgctt	gaacctgaga	ggcagagggt	gcggtgaact	1620
gagatcatgc	catagtactc	cagcctgggc	aacaagagtg	aaactccatc	tcaaaaaaaa	1680
aaaaaagaaa	aaaagataaa	gaaatgttct	cctttcttgc	catttctagg	ggtttgggga	1740
tggcgtacat	tgctgcaggg	cgtgctcact	ctaccatctt	gctccaatct	ttatttttca	1800
aaatacagtg	ccttatgcttg	gttacttcag	ttaagattat	ttttaaaaaat	cataattaag	1860
caaaaatata	tggccatgct	taaacatatt	taagataaat	taagtgattt	ggcctgtttc	1920
agtatcccaa	ctcacatgct	aacaggggct	tgacctgtag	ctacggtagc	ctggaggaaa	1980
tgatcgcat	tattttggtta	tttcggtcta	agtagtaata	gttctgtcct	gggaaaaaga	2040
ctagcctcaa	ggcatttctg	attgaatgtt	tttcaattac	agtctttaa	ccagtatgcc	2100
acagaactgg	ctctttccac	atgacggcct	ttgtgggtggg	tggcagattg	ccctgaggcc	2160
tcgcaaaatg	ctaggctttc	acaatgtcac	tgactgacag	ccaggcccag	cacagtcttg	2220
gtgtgattgt	ggggctaaag	ttattccacc	ttgtgcaata	gctacagcct	tctctaacca	2280
gctgcattct	tataaagtta	gaagaaaata	cctttttttt	tttgagatgg	attctcgctc	2340
tgttgcccag	gctggagtg	aatggtgcga	tctcggtctg	ctgcaacctc	cgctcctgg	2400
gttcaaacga	ttctcctccc	tcagaccccc	gagtagctgg	gattgcaggt	gcctgccacc	2460
acgcccggct	aacttttttg	tatttttagt	ggagacgggg	tttcaccatc	ttcgtcaggc	2520
tgggtctcaga	ctcctgacct	caagtgatct	gcccgcctca	gcctcccaaa	atgctgggat	2580
tacaggcatg	agctactgtg	cccggccaaa	gaaaataactt	tttatgccag	ccctgaaact	2640
accctgaagc	acatacatca	accttgaggc	ctcacactcc	atcaagaggg	gtgaagggca	2700
tgaggaatta	gaaagcatag	ggatttttag	ttagacagat	ctggttcaaa	tcctagactt	2760
gtgccttgaa	caaattat	accctcattg	aactctagat	tcattatttg	taaaatgaaa	2820
gacaataata	gttatctcca	aaggaaagtt	gaatatgac	attcatttat	tcattaattc	2880
aacattttatt	attgcctact	ttgtgccagg	ttctattcta	ggaactaagg	gatacaactt	2940
tgaataggca	aaatctctgc	tctcctgaag	tttacttttt	tttttttttt	ttgagacaga	3000
gtttcactct	tgtcaccag	gctggagcgc	aatggtgctc	ttggctcact	gcaacctcca	3060
cctcctgggt	tcaagtgatt	ctcttgtctc	agcctcccaa	gtagctggga	ctacagggtat	3120
gtgccaccac	gcccggctat	ttctgcattt	ttagtagaga	tggggtttca	ccatgttggc	3180
cagactgggtc	tcaaactcct	gatctcaggt	gatatgcctg	tcttggcctt	ccaaagtact	3240
gggattacag	gcctgagcca	ctgcacctga	cctgaagttt	atgttctatt	aaatagcaac	3300
agacagtaac	ataaaccaaa	aataaatagg	aaaacacat	aacaaaaatc	aaacagtgat	3360
ataattgaga	gttgcttcta	tttctttttg	ttgtcttctt	ggttcaatca	gcctgctaaa	3420
ctatatggaa	cctcattttc	atgggccaact	tattttaagc	gggggacctt	ggaaagtctc	3480
tcattgtctct	catctcaacg	gcctaattgtg	acttctcttg	aaatatattg	acattagcag	3540
gaagctgagg	cctttacatca	gatctttact	ttaattggtg	acttgacttt	actggtagat	3600
ttttaggctc	tgtgtggact	gtggagatga	tatctggggg	gcaggcagac	acttgccctg	3660
cctctgtctg	agaaaattct	gttttggatg	tcttgttgaa	gttgggtgctg	gcatacctaag	3720
cccttgctgg	ggtcgtaatt	taattcatca	gaatgtgtgg	cttgcaagaa	ccggctcaga	3780
tcctgcsctt	caaaaacaaa	acatgagcgt	gccaagaaag	tccaagggtg	tgaatgttgc	3840
cacttcaagc	ctaaactttc	taggaacacc	taagtgggtg	gcagcttcca	gttctccagg	3900
ctgcttctag	gccagagctg	ggttccacaa	gagacagaat	aggcatatat	atgcttaagg	3960
aactggaaaa	acaggctctc	tctctctcac	aaacacacac	acacacatac	caaggtagct	4020
gtcaaaatgt	tatccgaaat	tttggaaacca	aaaaatcttg	aaagatggta	ttccaatatc	4080
acatttttag	taagttttct	atttatattg	attcaaatta	cgattcgagg	ccacaagctt	4140
taagaattca	gggccttttt	aacttgccaa	gccccacacc	actccaggaa	cttccccaca	4200
ccccagttct	cagaattcat	gtgcaaggtc	tttccataat	ccagggtcca	ggtcagagag	4260
tggaggatgt	gctctatttc	ttacctgatt	gcagaccctc	ctgacagtgc	tcccttctga	4320
agcactcact	gtctgaacgt	acacagtctc	agacttaatc	atgcacagtg	agcaagactg	4380
tgggtgtgata	attggcgtcc	ctgactttat	agggcaaatc	tatgggaggg	ggagacctcc	4440
tggaccactg	agcaattaat	tcattttacat	taggaagttt	ctccgtcaga	tgcaggaaaa	4500

aaatcttgtt	ttcctgctgt	ggttttgact	tttgcccat	cttctgttgc	tgtttagga	4560
ggcaaaataa	gggtcaaggc	ctggaaacac	aagtgccttg	actgaagctc	cacttggett	4620
ccgaagccca	agctgggttg	taccaggttc	cctagggtgc	aggctgtggg	caactgccag	4680
ggactgtgct	ctgcccaccg	gcctctggcc	ctcactgagt	tggccaatgg	gaaatgacaa	4740
ttgtgaggtg	gggactgcct	gccccgtga	gtaccaggct	ggtgaggctg	ggccatctcc	4800
tcctcacttc	cattctgact	gcagtctgtg	gttctgattc	cataccagag	ggtaagagca	4860
attctgtgaa	gttccaggct	gggtggggga	tgcattgcata	gcctctggct	gggatcacc	4920
aggctctccc	gtccgtagta	gtgtgggagt	ggatacagg	ggatactctg	gtcagagcag	4980
cactgggtga	ggcagatatg	cactgggctt	cttctccgt	tctcccacag	ccccagaga	5040
gaaaggggta	tttcagacat	tccttctaag	atgcatggaa	ccattctgaa	ttttaccag	5100
ttcgctctgt	agcaggatac	ctattgagaa	aaagttagg	tcagtaagg	ggaagggtct	5160
gtccacagat	gaagtccaat	tcgattaagg	gggataagg	aatacattgt	ctcttagctt	5220
gaccaggtag	ggcaaaggaa	gaagcatata	tgaaggcagc	ttcagaaaag	tcaagctgag	5280
cactgacttc	agactggaat	taggaatcca	gctctgccac	tttattctac	tcagcaaata	5340
tttactgagc	aaattctatg	ggctagacag	tggattgggt	tcacaagata	caatgagtgt	5400
gacatgggtg	ttgtctatgg	atttgggat	atatgtagg	atagggatat	cttacaagg	5460
aatcaagagg	ttctaataag	gccagccatg	gtggctcaca	cctgtaatcc	cagcaatttg	5520
ggagaccgag	gcggtggat	cacctgaggt	caggagttcc	agactagcct	gaccaacatg	5580
gtgaaacccc	gcctctacca	aaaatacaaa	aattagttgg	gcgtgatggc	aggtgcctgt	5640
aatcccagct	tctcgggagg	ctgaggcagg	agaattgtct	gaacctggga	ggcagagggt	5700
gcagtgagcc	gagattgttg	ccactgcatt	ccagcctggg	tgacagagcg	agactttgtg	5760
tcaaaaaaaa	aaaaaaaaag	aaagaaaaa	aaaagaggct	ctaattgagat	aaaaatgagaa	5820
aagcctggca	tgtagtggca	acttatgaaa	aattgtaatt	aaaaaaaaaac	atthttctgac	5880
agaagaaact	ggatctacct	ggtttttctg	aagcctaata	ctgctcgccc	cagtgagtgc	5940
tgtttctgag	gcactcctgt	tgttttgagc	tgtggatgct	gaaggtaga	gtgggaggga	6000
ttttagaggt	taggtctgcc	cctctgtgt	tagaggacat	ggatccctgg	tctggagagg	6060
ttctgggttt	tggatcaagc	ctcacaaagg	gtggcaccac	ctcactccta	ggaactccgc	6120
tagaaggaag	gccagctctg	cctaattcgg	ttggggagat	gggggtccct	ttatgctagc	6180
agaatatgtc	cgaaggagca	tgatgggtgc	agctttgttc	atgaaggcca	gtggtacaca	6240
gggagcccg	cagcttctct	agcagtcct	gctgccactc	ttccttaagt	cttgaggagt	6300
cttttttttg	cacaatctca	gctcactgca	acctccgcct	cccaggttca	agcgattctc	6360
ctgcctcagt	ctcccaagta	gctgagacta	caggcatgcg	ccaccacgcc	cagctaattt	6420
ttatatTTTT	agtagagatg	gggttcacca	tattggccag	gatggctctg	atctcttgac	6480
ctcatattcc	acctgcctcg	gcctcccaaa	gtgctgggat	tacagggtgtg	agccactgcg	6540
cctggccgag	gagtccttaag	ctgagatcac	agcattgcac	tccagcctgg	gcaaaaagag	6600
caaaactcca	tctcaaaaaa	aaaaaaaaaa	tagacacaag	actggctcct	tgtctttttt	6660
ggggacaggg	tctcactcta	tcaccaggc	tggagtgcag	tgggtgcaatc	acagctcact	6720
gcagcctcga	tttcccaggc	tcaagtgcac	ctccactctt	agcctcctga	gtagctggga	6780
ctacagggtg	gtgcaaccat	gcctggctaa	tttttaaaaa	ttttttgtag	agatgagggtc	6840
tcactatatt	ggctgggggg	cctcaaactc	ctgggctcag	cagtcctccc	acctcagcct	6900
cccaaaaggc	tgggattata	tgcttgctct	ttttaagggtg	gctgtaggga	caaactttcc	6960
acctactcct	tgtcaagcca	gtggaccggt	ggtcccagac	atacggctaa	agtcaagagg	7020
tgatgtcttt	tggagagata	ctttcaatca	ggaatttcaa	tcagaaattc	aatcatgtgg	7080
agagagactt	atcctaataa	tgtggtgggtg	cgtgggatgc	tctgttttat	tagttccttg	7140
acagtatgta	tgtgtgtgag	tgtgtgtgtg	tgcgcgcgca	cactcatttg	gatgggtgtg	7200
tatgtgtgtg	ggggggtggt	gcgtacgtat	gtggatgtgt	ggatgtggtg	tgtgggtgtg	7260
cgcgtgcata	ggtggaggtg	tgtgtatggg	tgcgggtatg	tgtgtgtgtt	gggcatggag	7320
atattgacag	ctctcccagg	gctgagtga	ggctttcggg	caaagctcct	gggagctagg	7380
caaagctgag	ttgattcctg	gttatgccat	ttattattgg	gttgaccctg	gtgaaactgc	7440
caatattcta	cactttgact	tttatttatt	tttattttta	ttttttttga	gacagagttt	7500
cacacttgct	acctaggctg	gagtgcagtg	gcgcgatctc	agctcactgc	aacctctgcc	7560
tcatggattc	aagtgattct	cctgcctcag	cctcccaagt	agctggaatt	acagggtccc	7620
gtaccacgc	ctgactaatt	tttgattttt	tggtagagac	gggatttcac	catgttgtcc	7680
aggctgggtc	gaaactcctg	acatcaggta	atccaccac	ctcagcctcc	caaagtgcgtg	7740
ggattacagg	catgagccac	tgcgccggc	ccattttgac	tttttaaaaat	gggagtttga	7800
tataattcaa	tccagtggtt	gaattagcta	gcactgcttc	ctctccaagt	ctcagggtct	7860
cctacacgtt	agagtcaaaa	gcagggtat	gggaagatta	agtaaaaata	atthttgaaaa	7920
tgccttatga	aaattacact	ccaaagaact	cgcgccagtg	tcagtgttct	catgttctct	7980
atctcacatg	atcacatttc	gcggattagg	aagctgagtc	tgagaagctc	cgtgtagtgc	8040
tttttcggag	gcaccgtgat	gtgatggaag	gctcactcgt	taggaagtca	gaacagagtc	8100
tctgagggat	catttcctta	atctgtcagt	ttcctcatct	ctgaagtgtg	gctcatttcc	8160
ttccttcagt	gagttattgt	aaagatgaag	ataaataacg	tgtaaaatct	agcatgggaa	8220
ctggcttcta	taaggttcta	ataagtgcac	tctactcct	tccctcagc	cttcccattt	8280

gtaaaagcaa	ggcaggggtg	aggtgatttc	tggggctcct	tttggctctg	acatttgagg	8340
attttgtatc	cttttttttt	tcagagtctt	gctctgtcac	ccaggttggg	gtgcagctca	8400
atgcaaattc	cgctccccag	gctcaagcaa	ttcttatgtc	tcagcctcct	gagtacctgg	8460
gattacaggc	aggcaccacc	acccccagct	aattttttgt	attttcagta	gagacggggg	8520
tttgccatat	tggccaggct	ggtcttgaac	tcctgacttc	atgtgacca	cccatctcag	8580
cctcccaaa	tgctgagatg	acaggtgtga	gctaccgtgc	ctggccaatt	ttgtgtgctt	8640
taatgccctt	ttctgctgga	agagttggca	ccaggtttgg	tgatctcttt	ccccacacg	8700
gctctgcctc	ctgccagtcc	cagaggggac	cctgtccttg	catttcacag	gattctgctg	8760
ttgcaactga	aattccagta	ggtcaaagtg	aaattttotc	tacacttta	catgaagata	8820
aatgatcaca	gtatggccct	ttaggatcct	gagaacatca	cggtcatccc	ctggataaat	8880
tttaaaagca	gatgaatcca	tgcctgtgcg	aggtttgcca	ggaaagccag	tgctgggatt	8940
acagtggga	tctttttatg	ctactttttt	cttgtatccc	tcaccccatg	gggtggcata	9000
ttgaaaggca	ggatgtgtga	ccacgatact	tttctcctcc	tggactatgt	ctaagagtct	9060
gttattgggt	tctgaagatc	agagttta	ttccgactcc	tctctgtgta	gctctgggat	9120
cttggaagc	cacttaacct	ttctgaagtc	ccctttcctc	atctctaaaa	tgcatacact	9180
catcactaac	atttactgag	cactgacatg	tgccagacac	cattctaagc	attttacaca	9240
gactacacaa	tttgatcttc	caacaaacag	aacctgaaa	cgcattacag	gtcagaacaa	9300
atgattttgtg	cctaagcacc	aagaccgtag	agcccggtgc	ccctattcta	ccctatcctg	9360
tctctcaaaa	tgattgtgag	aatcgaatga	gacactaggt	gagaaaagg	ttttataaat	9420
agcattttta	aaatttttta	aagtcacaca	aatttttta	tttaatacag	ataaaataga	9480
tccctttgtt	ttataaaaag	taacaaaatt	tggtatacaa	caactatgtt	atttattaat	9540
tttgcccttt	tgtatgctgc	caggaaagaa	acattaagaa	atcttaaat	gattatgggtg	9600
aatcagaagg	tctgcctgga	ctttttattg	ctctaactgt	acagctgac	atactacctc	9660
attttttttt	atgacacttc	aaggggtgcg	ttagcttcat	cactccttcg	ttgccaaaag	9720
ctttgtgacc	aaaaacaatt	aagcagattc	ctgagtcact	aaatgacaca	taaccagagt	9780
tgagacttag	gaacttttag	tgccatgcta	agccacagag	gacacaacaa	atagcatttt	9840
acaaaggcaa	agaattgtga	cacttgagat	ttagcttgtt	gatccttgta	aaagttttct	9900
ttttaggcat	aattgagttt	tagatcatag	tactcactat	tacttagtaa	taattttttt	9960
ctgatagaaa	tacagtgtaa	caggccgggc	gcagtggctc	atgcctgtaa	tcccagcact	10020
ttgggaggcc	gaggcgggcg	gatcacttga	ggtcaggagt	ttgagaccag	cccgccaac	10080
atggtgaaat	cccatctcta	ctaaaaat	aaaaaattag	ccaggtgtgg	tcgtggattc	10140
ctgtgatccc	agctacttgg	gagggtgagg	caggagcctc	agttgaaccc	aggaggcgga	10200
ggttgcagtg	agccaagatg	gtgccattgc	actccagcct	gggccacaaa	gcgagactcc	10260
acttcagaaa	caaaaaaaaa	aagagagaga	gagaaaagaa	ggaaggaaag	aaggaaggaa	10320
ggaaagaagg	aaggaaggaa	ggaaagaagg	aaggaaggaa	ggaaggaaag	aaggaaggaa	10380
ggaaagaagg	aaggaaggaa	agaaggaaag	aaggaaggaa	ggaagggtta	caagcaaagt	10440
gtaacaatgg	caatatctaa	aaaaataggt	atttttatat	gtttgtcggt	ttatatatat	10500
gacccccact	ttagagatga	ggaaactgga	agattaaagg	aacgatccct	gagagactct	10560
gttctgactt	ccaatcggt	gagctttcca	tcgcatcacg	gtgcctccga	aagcatgaca	10620
cggagcttct	cagacttagc	ttcctaattc	gctaaacggg	attatgtgag	atgaggaaca	10680
tgagaacgct	gacatgggtg	agggttcctt	ggagtatcat	tttcatgtgg	catttttcaa	10740
acttattttta	cctaattctt	ccaaagccct	gcttttgact	ctaattgtgt	tcctgagact	10800
tggagagcgc	aagatgctag	cgacagagca	agactccatc	tccagataaa	taaataagta	10860
aaataaaaaa	gaacacaaat	aattttgaaa	atttttttga	aaattaggca	cgtttgcact	10920
gaccttcaat	tgttattaat	tgtctggttt	ccaccagaaa	ttaagttgga	atgcaacttt	10980
cttttacaat	cagagtccgt	tcttggctct	ggaaacttct	gaggctcctg	tgctaattccc	11040
actcttgat	ttttggcacc	tctaccccg	gccactgtca	tggaacccag	gctgatcgca	11100
cctattagtg	gagaaatmtg	tccataatac	tgaagtttgg	ggacaaacag	tggtccctta	11160
gggtaggaga	aagagatctt	tatttttaac	aaagggggag	gagccagaaa	actccagaga	11220
cccctgagtt	tgccctctct	ccaaggtttg	gggtaaagccc	cccgtcacc	tttatctctg	11280
gggtttcac	atattctgga	ttctctcctc	ctgtttccca	gcagaaaagg	atggagcctc	11340
acagattctt	cccatttctg	gagaaaaaca	tgcatggagc	tcaaagttct	tctcaggagt	11400
tttattgcca	aagccataat	aagaaagggt	ggaggtgaca	agcagtgagg	aagtttaaa	11460
atgcatgaaa	tctgtaaagt	ctcagaacaa	gaattctcct	aaaatgcaaa	aggggctttg	11520
ctggtctccc	cttggtctct	catgtagctc	acctcttttt	tcttatcttg	agactagtca	11580
aacctaaagt	gtttctcatt	ttatttccag	aagctattga	gaacactctc	ctgaattctt	11640
caaattcagt	agagggcgac	aaatgtacat	ataaatgatg	gtagtgggtc	ttaaataaag	11700
actcatgaca	cctaaagggg	cagcacctga	gtctgattgc	acctgtttct	gttgctgttt	11760
ctgtctctct	tctctctgtc	tgccatttca	ttatcaatgg	ttactttact	tataagatca	11820
tattagaacc	tgtatttga	taaatgatgc	atcagatcta	tagtgagaga	aaaaattaat	11880
gcaattaaag	gtgttgtaac	agctagtctt	caagtgggga	gaaatcattt	gagtacctta	11940
ggtcacagct	tacatcaaaa	caaaaaatca	gagctacatt	aaaaagtga	attttaacta	12000
tatcaaacaa	tagaaaaaaa	cagaagaaaa	ttgaataact	actaaatctt	agcatgaata	12060

agaactgttt	aacacttaga	ggcaaggact	gggcgtgggtg	gctcatgctt	ttaatcccag	12120
gactttggga	gcccagggcg	ggcgatcac	ctgaggtcag	gagtttgaga	ctagcctggc	12180
caacatgggtg	aaaccccgtc	tctactaaaa	aatgcaaaaa	ttagctgcgt	gtgggtgggtgc	12240
atgctgttaa	tctcagctac	ttgggagggt	aaggcatgag	aatcgcttga	acctggggagg	12300
tggaggctgt	agtgcgcca	gattgtgcca	ctgcactaca	gcctgggtga	cagtgtgaaa	12360
tcctctctct	caaaaaaaaa	aaaaaaaaaa	agcaactag	agcagtgagg	taccattatt	12420
tcctttgctc	actaaactga	caacacacaa	atgtttttta	taatacccaa	agctgatgag	12480
ggtagttaag	gtatgccctt	ttatacacac	actaatgatg	tactactggt	tggcagtata	12540
acatatgctg	ccatgtgggg	atatgtatca	ggagacttaa	aaatgtgcat	accttttgggt	12600
ccagtaattt	acttctggga	atctgtcata	acagaataat	aatcttgggg	aaagctacat	12660
gcctaaggat	atttaaaata	ttatttaaaa	atcaaagtat	aatttcttac	agaatataaa	12720
ataatatattt	aaaatgaaaa	tatgctaaaa	gtttgatgaa	atataaatgg	tcaaatatat	12780
attgattata	tccacttact	agactagcac	tcactctgag	acgttaaaaa	tagtcattat	12840
aaaaactaga	aaatgccaaa	gacaaaataa	aggaataaag	ttttacataa	agtatgattc	12900
cactatgttt	aaaaatpaac	agagacattc	ttggagttga	gtattgtttt	cttttctgtc	12960
atgtccaaag	aactatataa	ctattatttt	taatgaacta	tatatgtaat	atatacatat	13020
agtttatatg	tatatacaaa	atttatctca	tatatatgat	aaagatgaaa	gatgagttgg	13080
atgtgccacg	tgaagtgggt	agtatagaaa	cccaggtaat	ggggcatagg	agtgggattc	13140
cagataccag	gcccattgtt	ttgggggtgag	attgccaatc	acggtctttc	ttccatccct	13200
cacagaggag	taggtttgtc	ttcaacaaac	cttcagttgt	cctgaagaca	aacctaattc	13260
tggagacttc	atataatcta	gaagagacaa	gcaaaactgat	gaaaaatagt	gaatttttaa	13320
ggtaaaataa	agtacatgga	ctacactttg	tttagaatca	gattcttggg	attaaccaca	13380
ttaaccacaca	gagggtctta	gtgatgcctc	taatccagga	tcctaggacc	tatttctctc	13440
tgtgagatgc	tttctcccaa	ctccttgggtg	agagtgggaa	gactaagacc	tcagcaatct	13500
gaggtggagg	cctaagatcc	ccctaagatc	ggaggcgaaa	tctgagaggg	gataaaaagtc	13560
cctatacctg	tattgggccc	ttttctggga	gggggatatac	aaagaatgat	tttgagacag	13620
ggaggctttt	gactacctgt	gccacttgag	ctctttgtcta	gggctccaga	atacatattt	13680
caaatacatt	ccccctccct	ccttcccttc	ctcttccact	cttctttttt	atcttccctt	13740
cttcttttcc	ttctctcttc	ccttcccttc	tctggctctc	tcattgatttc	ttttctctcat	13800
tataaaagtg	cttattttagt	ccctactctg	ctattagtgt	gttagtcttt	gtcccttgggt	13860
acttgctgtt	taatggagaa	atgggtgagc	aaaacagaaa	ttacagcaga	gtgcaataat	13920
agagctaagc	caggtgtata	aatccattct	cacactgctg	taaaaaacta	ctgggtaatt	13980
tataaagaaa	agaggtttaa	ttgactcaca	gttccacagg	ctgtacagga	agcatggctg	14040
gggaggcctc	agaaaactta	caatcatgggt	ggaagaaaaga	gcgaagggga	agcaagcaca	14100
tcacacagca	gcaggagaga	gagagagaaa	gagagagaga	gagaatatag	gggaagtgtc	14160
acacactttc	aaccagatct	tgtgagaatt	cacctactat	catgagaaca	gcaagggata	14220
agtctgcctc	catgattcag	tcacctccta	ccaggccctc	tctccaacac	atgtcgacgt	14280
gctatttggg	tggggacaca	gacccaaaac	atattccagg	ggcactggag	aaacacagag	14340
gggaaagaac	cagccaagga	gtgagatgga	gaacaaggag	gacttcttga	aacagatgac	14400
atccaaaactg	ggtcctgaaa	gctgaataga	gattagacag	gggaggaggg	gcagctaaag	14460
atggctcagg	caaacaaagg	gccaggggat	atgttcatgg	gatgatgtgt	ctctcgttgt	14520
ctgcttaaca	caaggtgagt	ctctccctcc	ctctctctct	ctttttctct	gtgtgtgttt	14580
gtgtgtgtgc	atgtgtgcaa	atgtaatata	cccaatagtc	aaacatgtgc	cccaggagag	14640
gggtagagga	agaaagagaa	tgagagagta	agaaggagga	atagacacag	aaaatgagag	14700
agaagggggg	aaagaaaaag	aagaaaggag	ccagaggaga	gaagctgggt	agcattgaat	14760
ggagcaatct	gtgtcatcgt	acttgggaaa	cccaaggatg	gattcttggc	aagtcgactc	14820
ttggagcttt	ccctgtgctt	ggtcctgtgc	tcagacatgg	gaaaattaga	ggagtgtcat	14880
ctgtgcaate	actgaattca	taatcttggg	gaggaaagga	gactacacac	aggaataaat	14940
gctaagtatt	acagatttca	gggcagaaaag	agatcaagggt	gggctgcaat	attcagaaaa	15000
gtcttctctg	aaaagttgaa	tacttagaaa	gcagctccta	gaagtagact	ctgctgagat	15060
ggacggagtc	ctttgttaggt	cccaactggg	tgtgtgtgtg	gggtctgtct	ctccatggcy	15120
gacagtgcac	atgtggattc	cagggtcag	gatgctgttg	ctgggagctg	ttctactgct	15180
attagctctg	cccggkcatg	accaggaaac	cacgactcaa	gggcccggag	tcctgcttcc	15240
cctgcccaag	ggggcctgca	caggttggat	ggcgggcatc	ccagggcac	cgggccataa	15300
tggggcccca	ggcctgtgat	gcagagatgg	cacccctggt	gagaaggggtg	agaaaggaga	15360
tcagggtaag	aatgtttctg	gcctctttca	tcacagacct	cctacactga	tataaactat	15420
atgaagkcat	tcattattaa	ctaaggccta	gacacaggga	gaaagcaaaag	cttttttatg	15480
ttaaccataa	gcaacctgar	gtgatttggg	gttgggtcttc	caaggatgag	tgtatgtgtg	15540
gcctctataa	ccaagacttt	ggctttgtctg	catctgcagc	tccttttcca	tcctcttcc	15600
catcttcacc	ctcatcccta	ttcccagtag	attcatattc	tgattcctct	ttctgtctgc	15660
ttaaactoca	tttcaccacg	tggcattcaa	ccacatttac	tgcacacccc	ctgaaaggct	15720
cagtctgccc	tttggggaac	tcttgatcta	ggtaagatgt	ctaagtgtga	aggctctgtt	15780
ggtggttacc	acaagaaagt	ctactctaaa	aatgtcaaac	tgaatgtgaa	caagtattca	15840

aagtatggag	catagagaaa	atrtactcac	cgtggacctg	atgaagaatg	aaggcttcaa	15900
ggaggaggca	gagcttcagc	taggccttga	atgatgggta	ggcagaatag	aggaggagag	15960
acatcctaga	tggagggggg	agaattgcaa	aaccagggtt	gatggtgcca	gcacataaag	16020
ggctggcagg	gtggaggggtc	tatgatagag	acctatagga	gataaagata	gagttgaaat	16080
tatgggagcc	tccatgtctg	tgggagatat	agaaggagga	ggtaacacct	ctctcctttt	16140
gggagctctt	attggtttct	tgatctataa	gtcaagaagg	ttgtgagtgg	gagccacagg	16200
gatggtaatt	taggctgtaa	ccaacctagg	caggagttct	gttcttttga	gtcactgagg	16260
tcttctcatt	ccttaggtct	tattggtcct	aaggagagaca	tcggtgaaac	cggagtaccc	16320
ggggctgaag	gtccccgagg	ctttccggga	atccaaggca	ggaaaggaga	acctggagaa	16380
ggtgcctatg	tataccgctc	agcattcagt	gtgggattgg	agacttacgt	tactatcccc	16440
aacatgccca	ttcgctttac	caagatcttc	tacaatcagc	aaaaccacta	tgatggctcc	16500
actggtaaat	tccactgcaa	cattcctggg	ctgtactact	ttgcctacca	catcacagtc	16560
tatatgaagg	atgtgaagg	cagcctcttc	aagaaggaca	aggctatgct	cttcacctat	16620
gatcagtacc	aggaaaataa	tgtggaccag	gcctccggct	ctgtgctcct	gcactctggag	16680
gtgggagacc	aagtctggct	ccaggtgtat	ggggaaggag	agcgtaatgg	actctatgct	16740
gataatgaca	atgactccac	cttcacaggc	tttcttctct	accatgacac	caactgatca	16800
ccactaaactc	agagcctcct	ccaggccaaa	cagcccaaaa	gtcaattaaa	ggctttcagt	16860
acggttagga	agttgattat	tatttagttg	gaggccttta	gatattattc	attcattttac	16920
tcattcattt	attcattcat	tcatacaagta	actttaaaaa	aatcatatgc	tatgttccca	16980
gtcctgggga	gcttcacaaa	catgaccaga	taactgacta	gaaagaagta	ggtgacagtg	17040
ctatttttgtg	cccactgtct	ctcctgatgc	tcatatcaat	cctataaggc	acagggaaca	17100
agcattctcc	tgtttttaca	gattgtatcc	tgaggctgag	agagttaaagt	gaatgtctaa	17160
ggtcacacaa	gtattaagtg	acagtgcctag	aaatcaaacc	cagagctgtg	gactttgttc	17220
actagactgt	gccccttttat	agaggtacat	gttctctttg	gagtgttggg	aggtgtctgt	17280
ttcccacctc	acctgagagc	cattgaattt	gccttctctc	tgaattaaaa	cctcccccaa	17340
gcagagcttc	ctcagagaaa	gtggttctat	gatgaagtcc	tgtcttgga	ggactactac	17400
tcaatggccc	ctgcactact	ctacttcctc	ttacctatgt	cccttctcat	gcctttccct	17460
ccaacgggga	aagccaactc	catctctaag	tgtctgaactc	atccctgttc	ctcaaggcca	17520
cctggccagg	agcttctctg	atgtgatatc	cacttttttt	tttttttgag	atggagtctc	17580
actctgtcac	ccaggctgga	gtacagtgc	acgacctcgg	ctcactgcag	cctccttctc	17640
ctgggtccaa	gcaattattg	tgcctcagcc	tcccgagtag	ctgagacttc	aggtgcattc	17700
caccacacat	ggctaatttt	tgtattttta	gtagaaatgg	ggtttcgtca	tgttgggccag	17760
gctggtctcg	aactcctggc	ctagggtgatc	caccgcctc	gacctcccaa	agtgctggga	17820
ttacaggcat	gagccaccat	gcccagtcga	tatctcactt	tttattttgc	catggatgag	17880
agtcctgggt	gtgaggaaca	cctcccacca	ggctagaggc	aactgccag	gaaggactgt	17940
gcttccgtca	cctctaaatc	ccttgagat	ccttgataaa	tgcctcatga	agaccaatct	18000
cttgacatccc	gtactctacc	agaattaaact	ccactccagt	ctctgcatgt	aatcagtttt	18060
atccacagaa	acattttcat	tttaggaaat	ccctgggttt	aagtatcaat	ccttgttcag	18120
ctggacaata	tgaatctttt	ccactgaagt	tagggatgac	tgtgattttc	agaacacgtc	18180
cagaattttt	catcaagaag	gtagcttgag	cctgaaatgc	aaaacccatg	gaggaattct	18240
gaagccattg	tctccttgag	taccaacagg	gtcagggaag	actgggcctc	ctgaatttat	18300
tattgttctt	taagaattac	aggttgaggt	agttgatggg	ggtaaacatt	ctctcaggag	18360
acaataactc	cagtgatgtt	cttcaaagat	tttagcaaaa	acagagtaaa	tagcattctc	18420
tatcaatata	taaattttaa	aaactatctt	tttgcttaca	gtttttaaata	ctgaacaatt	18480
ctctcttaca	tgtgtattgc	taatcattaa	ggtattattt	tttccacata	taaagctttg	18540
tctttttgtt	gttgttgttg	tttttaagat	ggagtttccc	tctgttgcca	ggctagagtg	18600
cagtggcatg	atctcggtt	actgcaacct	ttgcctccca	ggttcaagcg	attcttctgc	18660
ctcagcctcc	cgagttagctg	ggaccacagg	catgccaggc	catgccaagg	taatttttgt	18720
atttttagta	aagacagggt	ttcaccatat	tggccaggct	ggtctcgaac	tcctgacctt	18780
gtgatctgcc	cacctccatt	tttgttgtta	ttttttgaga	aagatagata	tgagggttag	18840
agagggatga	agaggtgaga	gtaagccttg	tgttagtcag	aactctgtgt	tgtgaatgtc	18900
attcacaaca	gaaaacccaa	aataattatgc	aaactactgt	aagcaagaaa	aataaaggaa	18960
aaatggaaac	atttattcct	ttgcataata	gaaattacca	gagttgttct	gtcttttagat	19020
aagggttgaa	ccaaagctca	aaacaatcaa	gaccttttct	tgtatgtcct	tctgttctgc	19080
cttccgcagt	gtaggcttta	ccctcagggtg	ctacacagta	tagttctagg	gtttccctcc	19140
cgatatcaaa	aagactgtgg	cctgcccagc	tctcgtatcc	ccaagccaca	ccatctggct	19200
aaatggacat	catgttttct	ggtgatgcc	aaagaggaga	gaggaagctc	tctttcccag	19260
atgccccagc	aagtgtaac	ttgcatctca	ttgctctggc	tgagttgtgt	gocctgtttct	19320
gaccaatcac	tgagtcagga	ggatgaaata	ttcatattga	cttaattgca	gcttaagtta	19380
ggggtatgta	gagggtattt	ccctaaagca	aaattgggac	actgttatca	gaaataggag	19440
agtggatgat	agatgcaaaa	taatacctgt	ccacaacaaa	ctcttaaatgc	tgtgtttgag	19500
ctttcatgag	tttcccagag	agacatagct	ggaaaattcc	tattgatttt	ctctaaaatt	19560
tcaacaagta	gctaaagtct	ggctatgctc	acagtctcac	atctgggttg	ggtgggctcc	19620

ttacagaaca	cgctttcaca	gttaccctaa	actctctggg	gcagggttat	tcctttgtgg	19680
aaccagaggc	acagagagag	tcaactgagg	ccaaaagagg	cctgagagaa	actgaggtca	19740
agatttcagg	attaatgggc	ctgtgatgct	ttgaagtaca	attgtggatt	tgtccaattc	19800
tcttttagttc	tgtcagcttt	tgcttcatat	atcttagcgc	tctattatta	gatatatata	19860
tgtttagtat	tatgtcttat	tggtgcattt	actctcttat	cattatgtaa	tgctcttctt	19920
tatctgtgat	aattttctgt	gttctgaagt	ctactttgtc	taaaaataac	atacgacttc	19980
aacttccttt	tctttcttcc	ttcctttctt	tcttcttctc	tttctttctc	tctctctctc	20040
tttcttctct	tccttctctc	ttttctttct	ctctctctct	ctctctcttt	ttttgacaga	20100
ctctcgttct	gtggccctgg	ctggagttca	gtggtgtgat	cttggctcac	tgctacctct	20160
accatgagca	attctcctgc	ctcagcctcc	caagtagctg	gaactacagg	ctcatgccac	20220
tgcgcccagc	taatttttgt	atctttctgt	gagacgggg	ttcaccacat	tcgtcagggt	20280
ggtttcaaac	tcctgacttt	gtgatccacc	cgcctcggcc	tcccaaagtg	ctgggattac	20340
aggcatgagc	catcacacct	ggccaacttt	cttttgatta	gtgtttttgt	ggtatatctt	20400
tttccatcat	gttactttta	atatacttat	attattgtat	ttaaaatgtg	tttcttacag	20460
actgcatgta	gttggtgata	atctttatcc	agtctaaaaa	tatctgtctt	ttaattgggtg	20520
tttagacaat	ttatatttaa	taaaattggt	gaatttaaga	tggatgactg	ttttatttgt	20580
ttgctgttca	ccacttctgt	tttattctct	ttccagaatt	cttttggatt	gtttaaatat	20640
ttcataatat	tttatcttaa	tttatattat	gggtatttgc	ctatatctct	ttgtgggtatt	20700
ttttagtggg	tgcttgaggg	attacaatgt	acttaacttt	tcacagtgtg	cataaagtta	20760
atattttgcc	acttgacagta	aaccgtagaa	ggcttataat	catattagta	cctctatcca	20820
ctttctttta	tgttgtagtt	gtcatatata	ttacatctat	atacactgaa	acattatagg	20880
caatgttatg	atctttgcat	tcgtcagtc	tatatatatt	ttaaagaatt	taagaggaga	20940
aaaatacata	ttcagatatt	catcat				20966

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 2003/044057 A3

(51) International Patent Classification⁷: **A61K 38/22**,
A61P 25/28

(21) International Application Number:
PCT/IB2002/004924

(22) International Filing Date: 29 October 2002 (29.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/332,119 21 November 2001 (21.11.2001) US

(71) Applicant (for all designated States except US): **GENSET S.A.** [FR/FR]; Route Nationale 7, F-91000 Evry (FR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **LUCAS, John** [US/US]; 339 The Valley Road, Concord, MA 01742 (US).

(74) Common Representative: **GENSET S.A.**; c/o De Luca, Giampiero, Sersono International S.A., Intellectual Property, 12, Chemin des Aulx, 1228 Plan-les-Ouates (CH).

(81) Designated States (*national*): AE, AG, AI., AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PI, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
10 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF OBG3 FOR PROMOTING CENTRAL NERVOUS SYSTEM REMYELINATION

(57) Abstract: The present invention relates to the field of central nervous system (CNS) research. Demyelination of neuronal axons within the CNS underlies the pathogenesis of degenerative diseases of the neuromuscular system, such as multiple sclerosis and hereditary leukodystrophies. Therefore, treatments aimed towards accelerating the repair of myelin sheaths offer a potential therapeutic to ameliorate the symptoms of multiple sclerosis and leukodystrophies. A compound, globular OBG3, has been identified that has immunosuppressive properties. This compound should be effective for accelerating the rate of remyelination and treating multiple sclerosis and leukodystrophies.



WO 2003/044057 A3

INTERNATIONAL SEARCH REPORT

PCT/IB 02/04924

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/22 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, WPI Data, EMBL, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ALLAMARGOT C ET AL: "A single intracerebral microinjection of platelet-derived growth factor (PDGF) accelerates the rate of remyelination in vivo."</p> <p>BRAIN RESEARCH. NETHERLANDS 9 NOV 2001, vol. 918, no. 1-2, 9 November 2001 (2001-11-09), pages 28-39, XP002236251</p> <p>ISSN: 0006-8993</p> <p>the whole document</p> <p style="text-align: center;">--- -/--</p>	1-11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 April 2003

Date of mailing of the international search report

07/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Lechner, 0

INTERNATIONAL SEARCH REPORT

PC/IB 02/04924

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	YE P ET AL: "INSULIN-LIKE GROWTH FACTOR-I INFLUENCES THE INITIATION OF MYELINATION: STUDIES OF THE ANTERIOR COMMISSURE OF TRANSGENIC MICE" NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 201, no. 3, 1995, pages 235-238, XP001149310 ISSN: 0304-3940 the whole document	1-11
A	HALLEUX C M ET AL: "Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 16 NOV 2001, vol. 288, no. 5, 16 November 2001 (2001-11-16), pages 1102-1107, XP002236252 ISSN: 0006-291X the whole document	1-11

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-4, 7-11 (only partially)

Claims 1-4 and 7-11 (as far as relating to in vivo methods) are not acceptable under Article 6, PCT. The therapeutic application is functionally defined by a result to be achieved and pathophysiological mechanisms, respectively, i.e. regeneration or myelin sheaths of axons, increasing the rate of cellular division/migration of progenitor cells, inducing oligodendrocyte progenitor cells to differentiate into mature dendrocytic cells at sites of demyelination in axons and diseases in which demyelination of nerve fibres occurs.

However, this does not allow any practical application in the form of a defined, real treatment of a pathological condition (disease).

Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely the specific diseases listed in present claims 5 and 6.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-9, 11 (only as far as relating to in vivo methods) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-4, 7-11 (only partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.